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sUBePiDermAL AUtoimmUne BULLoUs DiseAses
Blistering of skin or mucous membranes can be caused by genetic, metabolic, chemical, physical, 
infectious, ischemic, toxico-endogenic, and autoimmune causes. Autoimmune bullous disease 
is an acquired immunological reaction to self-antigens in and below the stratified epithelium. 
The skin comprises two compartiments: the epidermis and the underlying dermis separated by 
an epidermal basement membrane zone (BMZ).1 Autoimmune bullous diseases are classically 
divided in those with an intra-epidermal blister, the pemphigus spectrum, and those with blister 
below the epidermis, the subepidermal autoimmune bullous diseases (sAIBD). In the latter 
autoantibodies are directed against self-antigens or autoantigens that reside in the epidermal 
BMZ. This thesis focuses on blisters caused by sAIBD.
The epidermal BMZ contains numerous highly specialized structures socalled hemidesmosomes 
that are composed of distinct polypeptides. At the top, the epidermal BMZ consists of the 
hemidesmosomal plaque followed by the plasma membrane of the basal keratinocyte. Under-
neath is the lamina lucida, that is electron-lucent in electron microscopy. The hemidesmosomal 
transmembrane molecules cross the lamina lucida and bind to laminins, in the skin the 
epidermis specific laminin-332.2 Underneath the lamina lucida is the lamina densa consisting 
of type IV collagen, nidogen and other structural components. Laminin-332 binds to type VII 
collagen.3 Type VII collagen is the main component of the anchoring fibrils and these are found 
in the sublamina densa zone, the lowest part of the epidermal BMZ. Various adhesion proteins 
are targeted in sAIBD (figures 1 and 2).
Hemidesmosomes (HD) contribute to the attachment of epithelial cells to the underlying 
basement membrane in stratified epithelia of the skin, cornea, mucous membranes of the 
gastrointestinal and respiratory tract and amniotic membrane..4 These proteins form the 
bridge between the cytoskeleton and extracellular matrix components.1,4 Hemidesmosomes 
appear in two different types: type I hemidesmosomes contain all components, whereas type 
II hemidesmosomes only consist of integrin α6β4, tetraspan/CD151, and plectin.5
-8 Type II 
hemidesmosomes are found in pseudostratified and cylindrical epithelia, e.g., those lining the 
gastrointestinal and respiratory tract, respectively. Type I hemidesmosomes are located in basal 
keratinocytes of multilayered stratified squamous epithelium.4,9 
Anchoring fibrils are filamentous structures that arcade below the lamina densa in the sublamina 
densa zone. The major component of anchoring fibrils is type VII collagen.10,11 Mutations in 
genes coding for the components of the dermal-epidermal anchoring complex as well as the 




figure 1. Illustration of the epidermis (left), lower aspect of the basal keratinocyte with the epidermal 
basement membrane zone (middle), and the hemidesmosome adhesion complex (right). [figure adapted 
from Jonkman MF,  Rulo HF, Duipmans JC. [From gene to disease; epidermolysis bullosa due to mutations in 
proteins in or around the hemidesmosome]. Nederlands Tijdschrift voor Geneeskunde. 2003;147:1108-13]
LABorAtory DiAgnosis of UnUsUAL AnD UsUAL vAriAnts 
of sAiBD
The sAIBD can be divided in common diseases  e.g. bullous pemphigoid, mucous membrane 
pemphigoid, linear IgA-dermatosis, pemphigoid gestationis, and less common or rare 
diseases e.g. anti-laminin-γ1 pemphigoid, anti-laminin-332 mucous membrane pemphigoid, 
epidermolysis bullosa acquisita, and lichen planus pemphigoides.
The laboratory diagnosis is made by analysing skin specimens and/or serum samples of the 
patients. For routine histopathological examination, a fresh vesicle or blister is biopsied at the 
edge of the blister (lesional), placed in formaldehyde, and processed for haematoxylin and 
eosin staining.12,13 Histopathology of a skin biopsy for bullous disease needs to look for type of 
infiltrate, structural abnormalities, and split level. The level of split allows differentiation between 
pemphigus and pemphigoid (sAIBD) spectrum which is intra-epidermal vs subepidermal 
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respectively. The infiltrate may give a hint for sAIBD, but by histopathology alone one is not able 
to demonstate sAIBD. 
For diagnosing sABID one needs to demonstrate depositions of immunoreactants in the 
epidermal BMZ by direct immunofluorescence microscopy (DIF) of perilesional skin. The biopsy 
must be snap frozen immediately and stored at -80 degrees or placed in saline or Michel’s medium 
suitable for later DIF testing.14 In sAIBD typically a linear deposition of IgG, IgA or complement 
is found along the epidermal BMZ. The linear depositions follow the BMZ in a serrated pattern. 
Analysis of these depositions by our group has revealed two types of serration patterns, a 
n-shaped and an u-shaped pattern. The sAIBD with their autoantigen located in or above the 
lamina densa, show a n-serrated immunofluorescence pattern, wheres the autoantigen located 
in the the sublamina densa zone, type VII collagen,  target in epidermolysis bullosa acquisita 
(EBA), IgA-EBA and bullous systemic lupus erythematosus (bSLE),show a u-serrated deposition 
pattern.15
The ultrastructural localization epidermal BMZ antigens can be determined by direct 
immunoelectron microscopy (DIEM) of immunolabelled semi-thin skin sections.16 In bullous 
pemphigoid (BP), mucous membrane pemphigoid (MMP) and pemphigoid gestationis (PG) 
the antibodies bind to the HD plaque and lamina lucida, and in EBA IgG binds in vivo in the 
sublamina densa zone with a “free zone” below the lamina densa.17-22 The upstanding arms of the 
sublamina densa zone between the rootlets of the basal keratinocytes seen at ultrastructural 
level in electron microscopy correlate with the u-serration (“grass”) seen at the microscopical 
level in DIF.15
Serum analysis for circulating autoantibodies is a valuable tool in laboratory diagnosis. The 
classical technique is indirect immunofluorescence microscopy (IIF) performed on frozen 
sections of standard substrates, including human skin, monkey esophagus, and rodent or 
monkey bladder. A valuable addition to these substrates was salt-split human skin, skin that has 
been incubated in 1 M NaCl what causes a separation of epidermis and dermis at the level of the 
lamina lucida (figure 2). 
figure 2. Schematic overview of 
the hemidesmosome (right) and 
the focal adhesion (left). Proteins 
to which autoantibodies are 
directed in sAIBD are stained in 
yellow. The epidermal basement 
zone can be consistantly split 
through the lamina lucida by 1.0 
M NaCl incubation, seperating 
the antigens of the epidermal 
and dermal compartment. 




Seperation of the epidermal and dermal compartment has two advantages, the sensitivity is 
increased through reduction of background fluorescence due to removal of endogenous non-
specific IgG and furthermore it allows discrimination between sAIBD with epidermal or dermal 
binding autoantibodies due to autoantigens in either the floor of the roof of the split.14 More 
sophisticated methods include fluorescence overlay antigen mapping (FOAM) analysis and 
IIF on socalled ‘knock-out’ substrate.23,24 FOAM is an IF technique developed in our laboratory 
which made it possible to visualise up to three immunoreactants in different colours in a single 
microscopic field of the epidermal BMZ. The technique can be used to differentiate between 
sAIBD’s that have targeted autoantigens within different levels in the BMZ. For instance, FOAM 
can differentiate between sAIBD with reactivity against laminin 332 and type VII collagen. IIF 
analysis on knock-out substrates is the analysis of serum performed on a substrate that misses 
the antigen of interest due to a genetic cause.25 We used plectin-deficient skin from a patient 
with epidermolysis bullosa simplex with muscular dystrophy (EBS-MD) homozygous for a null 
mutation in the plectin gene (c.G13187T, p.E1914X)26 to prove the existence of anti-plectin 
autoantibodies. Also, in chapters 2 and 3 we show that affinity-purified autoantibodies to 
plectin bind back to human skin and muscle. 
A further refinement of serum analysis in sAIBD are immunoassays that identify the targeted 
antigen, which are sometimes necessary for making the final diagnosis. For diagnosing sAIBD’s 
these include immunoblotting, immunoprecipitation and enzyme-linked immunosorbent 
assay (ELISA).
Immunoblot or Western blot is a method of semiquantitative determination of specific protein 
expression. Immunoblot allows to demonstrate reactivity to a protein in a mixture of any 
number of proteins while giving information about the size of the protein. For diagnostics the 
methods relies on the antigen-binding properties of the autoantibodies. In immunoblotting 
the binding properties depend on the type of detergent used, e.g. with the aggressive sodium 
dodecyl sulphate (SDS) proteins interactions are broken in a way that linear epitopes can be 
found. In contrast, conformational epitopes can instead be detected with milder detergents or 
other techniques like immunoprecipitation.
Immunoprecipitation (IP) is the technique of precipitating a protein complex out of solution 
using an antibody that specifically binds to that particular protein (antigen). The advantage of 
IP is that the technique can detect conformational epitopes, however some protein interactions 
might not be broken and can therefore not be detected. IP precipitates native protein complexes, 
such as the laminin-332 trimer, while immunoblotting demonstrates reactivity to individual 
polypeptides, such as the alpha3 laminin chain. 
The substrates for immunoblot and immunoprecipitation are extracts of cultured keratinocytes 
(cell extract), SCaBER cells, cultured A431 cells, tumor cell lines, or amnion.27-29 Also extracts of 
epidermis, dermis, recombinant (fusion) proteins, or spent culture medium can be used as a 
source of antigens. Some extracts have advantages over others: extracts of SCaBER cells, cultured 
A431 cells, and  amnion have the advantage that it contains the hemidesmosomal antigens 
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and type VII collagen in sufficient amounts, while cultured keratinocyte extracts are low in type 
VII collagen. Dermal extract contains type VII collagen, but generates too much background 
in immunoblot. Immunoblot with recombinant NC1, the C-terminal part of type VII collagen, 
is more sensitive and ELISA with recombinant NC1, the C-terminal part of type VII collagen is 
known in the literature as very senstitive and specific.30,31
Enzyme-linked immunosorbent assays (ELISAs), also known as enzyme immunoassay (EIA) is a 
diagnostic tool used to detect the presence and titer of specific antibodies in patient’s serum. 
Simply said, an unknown amount of antigen is affixed to a surface and then a specific antibody is 
applied over the surface so that it can bind to the antigen. In ELISA the antigens are present under 
native conditions, thus binding activity against conformational epitopes, which are epitopes in 
the original folded conformation of an antigen, is not lost. In contrast to immunoblot, ELISA is a 
quantitative method. Utilizing recombinant proteins that encompass specific regions of the BP 
antigens (e.g. the NC16A domain of BP180) are very specific as these domains contain various 
dominant epitopes to which these autoantibodies have been mapped.32-34 The usefulness of 
ELISA utilizing recombinant proteins of either bacterial or eukaryotic origin or affinity-purified 
native proteins of e.g. BP180 or laminin332 appears to be limited since 10-40% give false positive 
reactions in BP.35-37 Apart from initial diagnosis ELISA’s can also support therapeutic treatment. 
Schmidt et al. first demonstrated a positive correlation between clinical disease activity and 
antibodies to BPAG2 as detected by enzyme-linked immunosorbent assay (ELISA).38 Also in 
pemphigus ELISA seems also a tool to monitor the disease activity.39
As may be clear from the above a range of assay techniques is available, each with their 
own specificity and sensitivity. In this thesis we have used some of these sophisticated assay 
techniques in addition to the common routine assays to investigate if this results in a more 
accurate diagnosis (and possibly a higher incidence) (chapters 3,4 and 6) and to investigate the 
presence of possible rare or new antigens (chapters 3 and 6) in sAIBD. 
Antigens AnD sAiBD forms
Pemphigoids comprise the group of sAIBD of the skin caused by autoantibodies against the 
epidermal BMZ that contains hemidesmosomes and underlying extracellular matrix proteins.40 
HD are build from at least six different proteins, i.e. plectin, bullous pemphigoid antigen 1 
(BPAG1, BP230), bullous pemphigoid antigen 2 (BPAG2, BP180 or type XVII collagen), α6β4 
integrin and tetraspanin/CD151 (fig. 2).41-47 Autoantibodies against BP230 and BP180 are 
associated with bullous pemphigoid (BP), the most common variant of pemphigoid, as well as 
with pemphigoid gestationis (PG), lichen planus pemphigoides (LPP) and mucous membrane 
pemphigoid (MMP), whereas autoantibodies against the linear IgA disease antigen (LAD-
1), which is the soluble shed ectodomain of BP180, are found in linear IgA disease (LAD). The 
pemphigoid relevant extracellular matrix proteins comprise the soluble shed ectodomain of 
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BP180 (linear IgA dermatosis antigen, LAD-1), laminin-332 named after the α3, β3, γ2 laminin 
chains (formerly known as epiligrin or laminin-5), laminin-γ1 (p200) and type VII collagen.48
Bullous pemphigoid (BP) is a chronic sAIBD of the skin that affects mainly the elderly and is 
characterized by large, tense bullous lesions, may start as erythematous macules and urticarial 
papules or plaques usually associated with severe itching.49 The clinicopathological features 
of BP were first described by Lever in 1953.50-53 BP is associated with a humoral and cellular 
response directed against one or both of the two self-antigens BP180 (including it’s soluble 
shed ectodomain LAD-1) and BP230. BP180 is a transmembrane adhesion molecule with 15 
extracellular collagenous domains. Autoantibody reactivity to BP180 ectodomain is largely 
restricted to the NC16A region but may also be located near the carboxy-terminus.54 BP230 is 
a cytoplasmic protein involved in the anchorage of intermediate filaments to the cytoskeleton. 
BP230 and plectin, another protein of the hemidesmosome, both belong to the plakin family. 
Pemphigoid gestationis (PG, formerly named herpes gestationis; HG) is a pemphigoid form that 
is associated with pregnancy. In pemphigoid gestationis, a transient bullous eruption occurs in 
pregnancy most commonly in the second or third trimester but it may be present at any stage 
during the pregnancy or puerperium. Through placental transfer of autoantibodies to BP180 
from the mother into the neonate PG can also result in a blistering eruption of the neonate.55 
The clinical spectrum of PG is polymorphic and may include urticarial plaques and papules, 
erythematosquamous lesions and blisters. Autoantibodies in PG are mainly directed to BP180 
but incidental reactions to BP230 have also been reported.56-58  Like in BP, the NC16A domain 
of BP180 was shown to be recognized by a large number of PG sera, in fact NC16A is more 
frequently recognized as an epitope as in BP.59
Mucous membrane pemphigoid (MMP, formerly named cicatricial pemphigoid; CP) is a sAIBD 
of mucous membranes that sometimes also affects skin. Clinically, patients with MMP present 
with severe vesicles, erosions and crusts on mucous membranes with potential scar formation, 
typically affecting the oral cavity and eyes, but it also may affect the nasal, pharyngeal, laryngeal, 
esophageal and/or anogenital regions. Autoantibodies may react with two major regions of 
the BP180 extracellular domain, one is the NC16A domain (at or near the autoantibody site 
recognized by BP and PG) and the other is the carboxy-terminal tail.60-61 In 1992 a separate group 
of patients with MMP was described who had IgG autoantibodies against a set of disulfide-
linked polypeptides then referred to as epiligrin. This protein, also named nicein, kalinin and 
BP600 at that time, is identical to laminin-332.62,63 This form of MMP is known as anti-epiligrin 
cicatricial pemphigoid (AECP) or with its new name anti-laminin-332 MMP. Anti-laminin-332 
MMP is estimated to comprise 5% to 20% of all MMP cases. Clinical manifestations are mainly 
mucous mebrane blistering and potential scar formation. When lesions occur on the skin, the 
scalp, face and/or upper trunk are predilection sites.63,64 In chapter 5  we will investigate an 
exceptional patient with antibodies to laminin-332 but with abnormal clinical manifestation. To 
date, several epithelial components in the BMZ have been identified as autoantigens in patients 
with MMP. These include laminin-332 (α3, β3 and γ2 subunits), lamin-311 (α3 subunit, formerly 
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laminin 6), BP230, BP180, and the integrin a6β4 subunits.65 Seen the heterogeneity of MMP 
in terms of targeted antigen,  IIF on salt-split skin is important for diagnosis as floor staining 
will discriminate anti-laminin-332 pemphigoid from the other forms of MMP. As serum from 
EBA, bSLE and anti-laminin-γ1 patients also stain the floor, DIF analysis of skin depositions then 
becomes very important. All sAIBD’s which have their antigens located in or above the lamina 
densa, thus including anti-laminin-332 MMP and anti-laminin-γ1 (p200) pemphigoid, give a 
n-serrated IgG deposition pattern, thereby discriminating them from the diseases with type VII 
collagen as an antigen that demonstrate u-serrated IgG deposition.15,66
Lichen planus pemphigoides (LPP) is a rare sAIBD that presents with both lichen planus (LP) 
and BP lesions. It is characterized by vesiculobullous lesions arising on erythematous or normal 
healthy skin in a patient with coexisting LP. Blisters can occur before, meanwhile or after the 
development of lichen planus lesions. An interesting hypothesis is that the lichenoid infiltrate 
in LP may lead to damage to the BMZ and basal keratinocytes, and may unmask antigens or 
create new antigens within the BMZ.67 In contrast to bullous LP, where blisters are confined to 
LP lesions and a consequence of basal several basal cell degeneration found in histopathology 
LPP blisters appear in both LP lesions and previously unaffected skin. Immunologically, linear 
deposits of IgG and/or C3 at the BMZ in perilesional skin can only be found in LPP. LP lesions 
show fibrillar fibrin at the BMZ.67-70 Autoantibodies in LPP react with the C-terminal part of 
the NC16A domain of BP180, although some rare cases have been described with possible 
200 and 130 kD proteins.71-73 LP is a chronic inflammatory disease of skin, and oral and genital 
mucous membranes. Histopathology shows a prominent inflammatory band-like T-lymphocytic 
infiltrate with liquefactive degeneration of basal epithelial cells. It is unknown to which antigen 
the T cells are attracted in LP, but seen the location of the infiltrates it is not inconceivable that 
basal epidermal cells are involved. Seen the humoral component LPP we have investigated the 
sera of oral LP patients for possible autoantibodies to BP180 (chapter 4).
Linear IgA dermatosis (LAD) is an acquired sAIBD and a pemphigoid disease with exclusively 
IgA deposition along the epidermal BMZ. Clinical manifestations in LAD are heterogenous and 
may mimic other bullous diseases but mainly consist of vesiculobullous lesions affecting the 
skin and mucosal surfaces. Lesions may appear as a string of pearl-like or in a “crown of juwels” 
configuration. Initially, a 97-kDa protein was reported as target antigen in LAD, later the linear 
IgA antigen 1 (LAD-1) as a 120 kDa protein was found in medium of cultured keratinocytes. 
These proteins were identified as fragments of the shed BP180 ectodomain. Also BP180, BP230, 
and type VII collagen have been reported as targeted antigens.74-83 IgA to type VII collagen is also 
known as IgA-EBA or LAD-II.66,84-91
Anti-laminin-γ1 pemphigoid (formerly known as anti-p200 pemphigoid) is a recently discovered 
subtype of pemphigoid in which autoantigens are directed to the laminin gamma 1 chain that 
is located in the lower lamina lucida. Clinically, most reported cases present with tense blisters 
and urticarial eruptions, symptoms that closely resemble BP. 66,92
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Epidermolysis bullosa acquisita (EBA) is a sAIBD characterized by autoreactivity to type VII 
collagen in the anchoring fibrils and thereby the sole autoantigen located in the sublamina 
densa zone. Type VII collagen is composed of three identical α-chains. Each α chain consists of 
a central collagenous domain flanked by a 145-kDa non-collagenous amino-terminal domain 
(NC1) and a 30 kDa carboxy-terminal domain (NC2).90,91 EBA is a heterogeneous disease that may 
be characterized by either an inflammatory or a mechanobullous clinical phenotype. Bullous 
systemic lupus erythematosus (bSLE) is a bullous variant of systemic lupus erythematosus with 
autoantibodies against type VII collagen.93-95 BSLE is clinically characterized by a widespread and 
often transient, non-scarring vesiculo-bullous eruption, dramatically responding to dapsone. 
This inflammatory type of bSLE is in sensu stricto bSLE. BSLE can segregate into different 
phenotypes: an inflammatory one, which is more frequent, and a classical EBA-like phenotype, 
this is classic-EBA in SLE.
EBA can mimic other sAIBD diseases. The classic phenotype, first described by Roenigk et al. in 
1971 resembles the “classic dermolytic” form of inherited epidermolysis bullosa. Clinically the 
classic, mechanobullous phenotype mimics dystrophic epidermolysis bullosa hereditaria, while 
mild cases resemble acral blistering porphyria cutanea tarda, that heal with atrophic scarring, 
milia and hypo-or hyperpigmentation.96 Exclusive involvement of the scalp, neck and shoulders 
leading to scarring, resembles Brunsting-Perry pemphigoid.97 The inflammatory phenotype, first 
described by Gammon in 1984, mimics BP or MMP, clinically presenting with widespread vesicles 
or bullae involving intertriginous and flexural areas without milia formation or scarring.98,99 It may 
also present with grouped circinary vesicles and arciform erythema and then resemble LAD.87 
DIF of perilesional skin of EBA/bSLE shows an u-serrated pattern of depositions in upstanding 
arms (“grass”) of the sublamina densa zone between the rootlets of the basal keratinocytes.15,100
In chapter 6 we will investigate if the use of the serration pattern recognition by DIF increases 
the yield of EBA/bSLE diagnosis within the spectrum of sAIBD, and how the clinical phenotype 
varies among this subset.
ePiDemioLogy of sAiBD
BP  has an annual incidence ranging from 2.6 cases per million population in the Arabian Gulf to 
resp. 13 and 14 cases per million population in the north-west of Germany and the north-east 
of Scotland  101-106, with a rapid increase after the age of 60 years, it is a disease of the elderly. 
The 1-year survival in the US compared to Europe was item of discussion several years ago, 
since the frequencies of mortality-rate were resp. 11% in the US compared to 29-41% in Europe. 
Differences in age and general condition beyond different hospital care systems are plausible 
for the huge difference in numbers.107-111 Often, also MMP occurs in the elderly. Childhood LAD 
occurs at mean age of 4.5 years.112-114 EBA has been reported in both children and adults and may 
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occur at any age. As one of the more rare sAIBD in Western Europe, EBA has a reported annual 
incidence of approximately 0.25 per million.115
The hemidesmosomal proteins are far more frequently targeted in sAIBD than the proteins in 
the (sub)lamina densa zone. In the pemphigoid group (BP, MMP, PG, LAD and LPP) incidences 
per million reach from 2.6 to 14 in BP,101-106 1 in MMP,115 20 per million pregnancies in PG116,117 to 
incidences that are less well known as in LAD (ca 4 to 6 per million)118-120 while the incidence 
of LPP is estimated 2 to 3 per million.102 In contrast to LPP, lichen planus is a far more common 
disaese and reaches incidences from 0.22% to 2% of the adult population.121,122
For the more common sAIBD, techniques such as ELISA and immunoblot are well developed to 
detect the antigens. But what if other rare autoantigens are present? Are the current techniques 
sufficient to reach the diagnosis or do techniques need to be adjusted or newly developed? 
How to find rare diseases or common diseases with additional rare antigens? In this thesis we 
hope to find answers to these questions.
immUnoLogy AnD ePitoPe mAPPing
The immune system protects us against all kinds of potential pathogens as bacterias, parasites 
and viruses. Unfortunately, the system does not function without faults and sometimes becomes 
activated against our own body. In autoimmune diseases an immunological reaction is present 
against self-molecules. 
The immune system consists of a non-specific innate and a specific adaptive immune system. 
The innate immune system provides immediate defense, while the acquired ‘adaptive’ immune 
system takes to time to respond. Both immune systems contain humoral mechanisms of 
defensive strategy against pathogens and cellular components. Antigen and antibody interact 
due to complementarity in shape and fit together precisely in a “lock and key” manner. In 
autoimmunity the adaptive immune system plays a major role.
isotypes
Immunoglobulins (antibodies, Ig’s) have different structural variants (isotypes or classes) 
based on different heavy chain domains. In human beings there are five major types of heavy 
chains giving five classes of Ig, named IgG, IgA, IgD, IgE and IgM. IgG is the most abundant Ig, 
particularly in the extravascular fluids where it neutralizes toxins and combats microorganisms 
by activating complement. IgA is present as a dimer linked to a secretory component and exists 
mainly in mucous membranes and in secreted fluids as tears, saliva and breast milk. In the 
mucous secretions it is the major Ig. IgM provides an early defense as it is the first Ig produced 
and therefore acts before sufficient IgG is present. Immunoglobulin D is a cell surface receptor 
largely present on the lymphocyte and functions together with IgM as the antigen receptor on 
naïve B-cells. Immunoglobulin E triggers inflammatory reactions, it binds to the Fc-receptor on 
21
Introduction
mast cells and when it binds an antigen this leads to local recruitment of antimicrobial agents 
through degranulation of the mast cells and release of inflammatory mediators. Autoimmune 
responses may be limited to one single class but may also exist of more classes. Different classes 
may exert different clinical manifestations. For example when IgA forms the major or only 
immune response this could lead to a higher degree of involvement of the mucosa.
All classes, with the exception of IgD, have been found as autoantibodies in sAIBD. Interaction 
between IgG, IgA or IgE and Fc receptors on binding antigen-associated antibody can lead to 
immunoregulatory reactions trigger effects such as phagocytosis, antibody-dependent cellular 
toxicity and acute inflammatory responses. 
More than 90% of BP patient sera contain IgG autoantibodies that bind the BP180 and/or BP230 
protein.123-125 IgA and IgE autoantibodies are also frequently found in 22-89% of BP sera.126-128 
Patients with MMP often have additional IgA autoantibodies directed against the ectodomain 
of BP180.129 Recently, circulating IgA and IgE autoantibodies in anti-laminin 332 MMP have been 
described as has been known for BP for several years.130-138 LAD is by definition a solely IgA-
mediated disease. 139
EBA was first described in 1971 as a IgG-mediated disease resembling dystrophic epidermolysis 
bullosa.96 In 1984 Gammon for the first time described a pemphigoid-like EBA patient.98 An 
IgA-mediated subtype of EBA was then described in 1994 by the group of Zambruno140 , and 
reviewed by Vodegel et al.87 In chapter 6 we investigate if the different immune responses to 
type VII collagen are connected with different clinical phenotypes. 
Concomitant antigens
Patients with sAIBD can have more than one targeted antigen. Well known examples are 
the concomitant antigens BP180 and BP230 which are frequently both targeted in BP while 
these antigens are closely located in the hemidesmosome. Other close targeted antigens 
are laminin-332 and type VII collagen, which are described in the literature in one particular 
patient.141 Also, subepidermal bullous disease has been described with autoantibodies to both 
the p200 autoantigen and the alpha3 chain of laminin-332. An example of intermolecular 
spreading is e.g. a patient in which autoantibodies are both targeted to the hemidesmosome 
and to type VII collagen.141-144 The phenomenon of “epitope spreading” has often been used as 
an explanation why different antigens are targeted.145,146 Epitope spreading is the development 
of immune responses to endogenous epitopes secondary to the release of self antigens during 
a chronic autoimmune or inflammatory response.
epitopes
The part of the hypervariable regions on the antibody that actually contacts the antigen is 
termed the paratope, and the part of the antigen which is in contact with the paratope is called 
the epitope or immunodominant site. Each B-cell synthesizes an immunoglobulin specific to 
only one epitope. The recognized epitope determines where on the protein the antibody binds. 
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The question if recognition of a specific epitope leads to specific disease features is ongoing. 
The best studied antigen in this respect is BP180. In bullous pemphigoid the immunodominant 
epitope of BP180 is NC16A, which consists of five subdomains, named MCW-0 to MCW-4 
(or NC16A subdomain 1 to 5). In BP three regions (NC16A subdomain 1 to 3) on NC16A are 
targeted. Other parts of BP180 that contain epitopes are the intracellular domain where  IgE 
autoantibodies are reported to bind.147 In PG also the NC16A domain is targeted, but here 
domains 2 and 3 react.148,149 The immunodominant epitopes in LPP are located in NC16A4 
subdomain.150 Heterogenous binding with autoantibodies to BP180 NC16A was demonstrated in 
MMP patients.60 Another major epitope in MMP is located in the extracellular carboxyl-terminal 
domain of BP180.61 This means that in MMP, IgG is deposited in the lamina lucida and the lamina 
densa. Involvement of the lamina densa may explain the susceptibility to scar formation in 
MMP.151 Pure oral pemphigoid (OP), presenting with exclusive oral lesions, was recently studied 
by epitope mapping. OP patients without scarring lesions showed preferentially autoantibodies 
which targeted the BP180 extracellular domain.152 For BP230, other major autoantigen in BP, 
epitope mapping demonstrated multiple antigenic reactive sites located predominantly within 
the B and C subdomains of the COOH-terminus of BP230.153 In EBA there are four major epitopes 
along the N-terminal part of type VII collagen (NC-1) that are targeted by IgG autoantibodies 
in mechanobullous EBA patients (figure 3).154-155 For inflammatory EBA, although several case 
reports have suggested that the triple helical domain of type VII collagen is the major targeted 
domain, this is rather unusual.156-164  The major target of autoantibodies in this subgroup might, 
as well as in mechanobullous EBA, be the NC-1 domain. For IgA EBA the immunodominant site 
is still unknown.
To study effects of epitope use of animal models could be useful. Well characterized antibodies 
can be injected to study their clinical effect. Such studies are also interesting in relation to drug 
development.
figure 3. Schematic overview of type VII collagen with on the amino-terminal part of the protein (left) 
three chains of the non-collagenous-1 domain (consisting of the cartilage matrix protein, nine fibronectin-
III repeats and a subdomain resembling von Willebrand factor A) connected to one central collagenous 
domain and to another three chains of the non-collagenous-2 carboxyl terminal part (right).
Aim of the study
In these study we report in depth on the clinico-immuno-histopathological phenotype of 
unusual or rare variants of subepidermal autoimmune bullous diseases




The next chapters of this thesis focus on rare autoantibodies in the more common diseases.  In 
chapter 3 we study plectin as autoantigen in pemphigoid. In chapter 4 we investigate sera of 
oral lichen planus patients for a serological association with pemphigoid. In chapter 5 we will 
focus on a case with anti-laminin 332 autoantibodies but with a completely aberrant clinical 
presentation.
In chapter 6 we analyse the variance of epidermolysis bullosa acquisita phenotypes and the 
immunoglobulin class responses and investigate if these are correlated to the clinical phenotype. 
This study was performed in our national bullous diseases reference centre at the department 
of Dermatology of the UMCG. The centre hosts a large biobank of sera and biopsies that date 
back to the seventies. As part of the standard diagnostic procedure for patients suspected of 
sAIBD, biopsies and serum are taken from each case referred to us. After diagnostic procedures 
the samples were stored in our biobank at -80C. The large number of samples in this collection 
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We present a case of inflammatory epidermolysis bullosa acquisita (EBA) with IgA antibodies 
to plectin. Analysis of lesional skin biopsies by electron microscopy revealed the split level to 
be in the sublamina densa zone, fitting with the diagnosis of EBA. Direct immunofluorescence 
of perilesional skin demonstrated u-serrated depositions of IgG and IgA that under 
immunoelectron microscopy were shown to be located in the sublamina densa. In contrast, 
indirect immunofluorescence on salt-split skin revealed circulating IgA antibodies that stained 
the roof rather than the floor of the blister. Immunoblotting showed these serum antibodies to 
be directed to the cytoplasmic hemidesmosomal antigen plectin. The anti-plectin specificity 
of these antibodies was confirmed by ‘knock-out’ immunofluorescence analysis: the serum IgA 
did not bind to skin sections of a patient with plectin-deficient epidermolysis bullosa. To our 
knowledge, this case demonstrates for the first time the existence of IgA antibodies against 
plectin.
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introDUCtion
Epidermolysis bullosa acquisita (EBA) is a chronic subepidermal bullous autoimmune disease 
with autoantibodies against type VII collagen. Two clinical variants are recognized: the classic 
type with trauma-induced blisters, milia and dystrophic nails, and the inflammatory type with 
acute blisters on an erythematous base resembling bullous pemphigoid or less commonly 
cicatricial pemphigoid.1
rePort
Here we describe a patient with an impressive chronic blistering disease who visited our clinic 
from 1976 until her death in 1987. Although a ‘cold’ case we reopened her file as the diagnostic 
potential of laboratory assays has significantly increased in the intervening years. At her visit to 
us, the patient was 70 years old and suffering from severe itch of 1 year’s duration. In 1970 she had 
undergone a total breast amputation because of adenocarcinoma, but no signs of metastasis 
were found during follow up. She was being treated with propranolol for hypertension. 
Physical examination showed annular erythematous macules, papules, vesicles and bullae at 
the wrists, trunk and lower legs. Milia were present and some blisters had healed with scarring. 
One year after referral the mucous membranes of the oral cavity also became involved (figure 
1). Treatment with prednisolone 25 mg daily showed a good response initially; however after 
tapering the dosage the symptoms relapsed. From 1977 to 1987, treatment was attempted 
with 50-100 mg dapsone daily for years, 50-100 mg azathioprine daily for 4 years, and systemic 
and topical steroids, but with little or no durable effect. Until her death in 1987 from a cardiac 
infarction, the patient continued to have the itchy blistering disease, hypertension, and angina 
pectoris.
figure 1. (a) Tense vesicles 
and bullae with serous content 
and erosions on figurate 
erythematous patches and 




Histopathology of lesional skin showed an infiltrate-poor subepidermal blister, with a few 
neutrophilic granulocytes in proteineous blister fluid. Acantholysis was absent. Subpapillary 
oedema and granulocytes in the dermal papillae were occasionally seen. Electron 
microscopy revealed the cleavage level to be in the sublamina densa zone (figure 2a). Direct 
immunofluorescence (IF) of perilesional skin showed linear staining of IgA and IgG along the 
basement membrane zone (BMZ). At first the IgA dominated, but later on IgG became more 
prominent. Both depositions were of the u-serrated type, recently described as indicating 
antibodies targeting type VII collagen (figure 2b).2 Immunoelectron microscopy on frozen 
sections showed the IgA and IgG depositions to be confined to the sublamina densa zone 
(figure 2c).3 
figure 2. Skin biopsy analysis indicates epidermolysis bullosa acquisita.
(a) Electron microscopy of lesional skin reveals separation (*) in the sublamina densa zone. (b) Direct 
immunofluorescence analysis of perilesional skin shows an u-serrated pattern of IgA deposition along the 
basement membrane. 
Serum IF for BMZ antibodies performed on monkey oesophagus substrate had always been 
negative. Repeat testing on the more sensitive salt-split skin substrate showed that the IgA 
surprisingly labelled the roof of the split (titre 1/10). Immunoblotting showed circulating 
antiplectin IgA antibodies (figure 3a) with no reactivity against other antigens, including type 
VII collagen.
To verify that these immunoblot binding antibodies could also bind to skin, we eluted the IgA 
from the blot, and using IF microscopy showed that on a section of normal human skin, it bound 
in a pattern corresponding with the distribution of plectin, i.e. along the BMZ and around the 
cell borders of keratinocytes (not shown).
Plectin is a member of the plakin protein family and is expressed in a variety of cell types 
including muscle and epithelial cells. It mediates the network formation of intermediate 
filaments, the interlinking these to microtubules and microfilaments, and anchoring them to 
the plasma and nuclear membrane. Absence of plectin results in epidermolysis bullosa simplex 
with muscle dystrophy (EBS-MD).4 
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Plectin-deficient EBS-MD skin was used as IF substrate for further proof that the serum IgA was 
directed to plectin. Where the patient’s IgA bound the BMZ of normal skin, no binding was seen 
to plectin-deficient skin (figures 3b,c). 
figure 3. Serum IgA antibodies are directed to plectin.
(a) Immunoblot analysis of patient serum shows IgA binding to several high molecular weight protein bands 
(lane 2) completely identical with the binding pattern of anti-plectin monoclonal antibody HD-121 (lane 3).13
The additional lower band seen with the patient serum was non-specific as it did not bind to skin after 
affinity elution. Lane 1 shows a control serum of a LAD patient with IgA antibodies against BP180. (b) Patient 
serum IgA binds to the BMZ of normal human skin, but does not bind to plectin-deficient EBS skin (c). 
The final diagnosis of inflammatory EBA was based on the clinical picture in combination with 
the split level, the sublamina densa deposition and the u-serrated IF pattern. The serum results 
seemingly contrasted with the EBA diagnosis. In salt-split skin analysis, a roof staining was 
visible, which by immunoblot, affinity-purification and ‘knock-out’ IF analysis was demonstrated 
to be caused by anti-plectin antibodies. Apparently the anti-type VII collagen antibodies, which 
deposited in vivo, were of such low titre that they could not be detected by salt-split analysis. 
This is common in around half of EBA patients, for whom, despite clear skin immunodepositions, 
no circulating antibodies were found.5 That the roof-binding IgA antibodies were directed to 
plectin was surprising.
To date, reports on anti-plectin autoantibodies are rare. So far only one case has been observed 
and this clinically resembled bullous pemphigoid.6 In paraneoplastic pemphigus (PNP), the 
incidence of anti-plectin IgG appears higher, as Proby et al. found 13 cases with anti-plectin IgG 
among 16 PNP patients.7 IgA to plectin, as in our patient, has not been described previously 
and the pathological significance of our finding is not yet clear. As the blister was formed in the 
sublamina densa zone the anti-type VII collagen antibodies in this particular case appear more 
pathogenic than the IgA to plectin. 
In perilesional skin we did not detect deposition of IgA at the inner hemidesmosomal plaque, 
and likewise we found no n-serrated pattern in direct IF, as would have been expected if 
deposition had occurred at the hemidesmosome.2 This indicates that plectin antibodies cannot 
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reach their intracellularly situated target in intact keratinocytes, but cell damage allows entry to 
the antigen. Nevertheless, the rare combination of antibody specificities may have contributed 
to the severe clinical pattern. Two inflammatory EBA cases with additional antibodies have been 
described previously, with accompagnying IgG against, respectively, laminin-332 and BP180.8,9
These dual responses may reflect epitope spreading, a process by which, owing to tissue 
damage from an autoimmune inflammatory process, exposure of a previously ‘sequestered’ 
antigen leads to a secondary autoimmune response to this new antigen.10
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Background: Hemidesmosomal proteins may become targets of autoimmunity in subepidermal 
blistering diseases. Well-known recognized auto-antigens are the intracellular plaque protein 
BP230, the transmembrane BP180 and its shed ectodomain LAD-1.
objectives: The aim of the study was to establish the prevalence of autoimmunity against 
plectin, another intracellular plaque protein, and to investigate its antigenic sites. 
Patients/methods: Two hundred and eighty two patients with subepidermal blistering diseases, 
investigated by routine immunoblot analysis for possible anti-plectin antibodies, were included 
in the study. Epitope mapping was performed using recombinantly produced overlapping 
plectin domains from the actin binding domain to the rod domain. The COOH-terminal region 
of plectin was not included in the study.
results: In 11 out of 282 (3.9 %) patients an immunoblot staining pattern identical to that of 
anti-plectin monoclonal antibody HD121 was found. Affinity-purified antibodies bound back to 
normal human skin in a pattern typical for plectin, i.e. to the epidermal basement membrane 
zone as well as to keratinocytes in the epidermis, and to myocytes. No binding was seen to 
plectin-deficient skin of a patient with epidermolysis bullosa simplex with muscular dystrophy. 
Epitope mapping of the plectin molecule showed that the central coiled-coil rod domain is an 
immunodominant hotspot as 92% of the  sera with anti-plectin antibodies reacted with it. Most 
patients with anti-plectin antibodies also had antibodies to other pemphigoid antigens. 
Conclusions: Plectin is a minor pemphigoid antigen with an immunodominant epitope located 
on the central rod domain.
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introDUCtion
Plectin is a widely expressed high molecular weight protein found in different cell types, 
including muscle and epithelial cells. In keratinocytes the plectin 1a isoform, a full length 
plectin variant (> 500 kDa) containing the sequence encoded by the alternative first exon 1a, 
is localized in hemidesmosomes and desmosomes, and in muscle cells it is associated with 
the sarcolemma.1-3 Plectin is involved in anchoring of intermediate filaments to the plasma-, 
and nuclear membrane, as well as the cross-linking of intermediate filaments, and interlinking 
intermediate filaments with microtubules and microfilaments.4,5 Plectin is part of the plakin 
protein family together with desmoplakins I and II, envoplakin, BP230, periplakin, epiplakin 
and MACF,4,6 that all probably arose from a single precursor gene.7 The protein contains a long 
central rod domain with an alpha-helical coiled coil conformation that is flanked by globular 
NH2- and COOH-terminal domains.5 The central rod domain is also found in four other family-
members: desmoplakin, envoplakin, periplakin, and BP230. The N-terminal part harbours an 
actin-binding domain and a plakin domain which both are also involved in binding to the 
integrin β4 subunit.8-10 The COOH-terminal is made up of six plakin repeat domains, a linker 
subdomain located between the 5th and 6th  repeat and a glycine-serine-arginine domain. 
Intermediate filament proteins vimentin and cytokeratins (K8/18) bind to the COOH-terminal 
plectin domain at the linker region between the 5th and 6th repeat domain and the 5th repeat 
contributes to binding.8,9,11,12
Pemphigoid is a group of subepidermal bullous autoimmune diseases of the skin caused by 
autoantibodies against the epidermal basement membrane zone (BMZ).13 Autoantibodies 
against BP230 and BP180 are associated with bullous pemphigoid (BP), the most common 
variant of pemphigoid, as well as with pemphigoid gestationis (PG), lichen planus pemphigoides 
(LPP) and mucous membrane pemphigoid (MMP), whereas autoantibodies against the linear 
IgA disease antigen (LAD-1), which is the soluble shed ectodomain of BP180, are found in linear 
IgA disease (LAD).14-16 
Plectin also appeared to be recognized by autoantibodies in immunobullous diseases. 
Paraneoplastic pemphigus (PNP), a rare form of pemphigus with an underlying neoplasm, is 
characterized by an unique immune response against plakin family proteins, and plectin was 
found among these.17,18  In 2000 Ohnishi et al. had described a patient with a vesicular form of 
pemphigoid and IgG antibodies against a 450 kDa protein.19 Originally thought to be plectin 
this protein was later identified as epiplakin instead.20 Although epiplakin belongs to the 
plakin family it is structurally different from plectin and encoded by a different gene. At the 
same time using a combination of immunoprecipitation and immunoblotting Laffitte et al.21 
were able to show IgG anti-plectin antibodies in a five-month-old child who clinically suffered 
from bullous pemphigoid. We recently described a case of epidermolysis bullosa aquisita (EBA) 
with concomitant IgA antibodies to plectin.22 To date, no other reports exist of immunobullous 
diseases with plectin autoantibodies.
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In our laboratory sera from patients suspected of autoimmune bullous diseases are routinely 
screened by immunoblotting for presence of pemphigoid autoantibodies. We then noticed 
that some patients bound to the blot in high molecular weight patterns similar to the pattern 
obtained with plectin monoclonal antibodies. Here we therefore set to demonstrate that plectin 
indeed is an autoantigen in bullous pemphigoid, to identify its incidence in immunobullous 
diseases, and to identify the site of binding on the plectin molecule. 
mAteriALs AnD metHoDs
Patient sera
As part of the Center for Blistering Diseases at the University Medical Center Groningen our 
laboratory performs diagnostic assays on biopsies and sera of patients suspected of an 
autoimmune bullous disease. In this study we used sera that we received over a time span of 
seven years (1997 to 2003). All sera used were initial sera of our own clinic or earliest diagnostic 
samples sent to our referral centre. We retrospectively analyzed the immunoblot patterns of these 
sera and selected those sera that displayed reactivity with one or more of the hemidesmosomal 
antigens BP230, BP180, LAD-1 or the suspected plectin. To ascertain that we only included 
sera from patients with proven subepidermal autoimmune diseases, we further selected only 
those samples for which immunofluorescence analysis confirmed such diagnosis. Therefore the 
included sera had to meet to the following criteria: if both serum and biopsy were available then 
the serum was included if the biopsy demonstrated a linear deposition of IgG, IgA or both along 
the epidermal BMZ, if only serum was available then the serum had to display binding along 
the BMZ on monkey oesophagus and/or along the roof of salt-split human skin. Two hundred 
eighty two sera met the inclusion criteria; of these 226 had only IgG antibodies, 11 had only 
IgA antibodies and 45 had both IgG and IgA antibodies. The case files of the patients seen at 
our own clinic showed that majority of the patients had BP while the others had PG, LPP, MMP 
or LAD. Eleven sera, that displayed a possible plectin pattern on immunoblot, were selected for 
further characterization. In these additional studies we also included, as a positive control, the 
first patient that we discovered with possible plectin antibodies, and who was a special case 
of EBA with concomitant IgA to plectin.22 We used two sera from this patient (#7 in this study); 
a serum from 1979 and a serum from 1985. Both sera displayed the same immunoblot plectin 
binding characteristics. 
recombinant plectin constructs
The generation of the recombinant, hemagglutinin (HA) epitope tagged, plectin proteins used 
in this study has been described before.10 In brief, cDNAs encoding polypeptide sequences of 
the plectin 1a variant were subcloned into the multicloning sites of the eukaryotic expression 
vector pcDNA-HANII (Invitrogen), which allows expression of a recombinant protein that 
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is tagged with HA at the N terminus. All nucleotide and amino acid positions are numbered 
with the ATG initiation codon at position one (GenBank accession no. U53204). Plasmid inserts 
were generated by restriction enzyme digestion or polymerase chain reaction (PCR) by using 
the proofreading Pwo DNA polymerase (Roche Diagnostics, Indianapolis, IN) and gene-specific 
sense and antisense primers containing restriction site tags. Seven recombinant plectin-
constructs were generated: (a) plec1–339 containing the actin-binding domain (ABD), (b) plec1–606, 
(c) plec1–1154 containing both the ABD and the plakin domain, (d) plec1–2532  containing the ABD, 
the plakin domain and the coiled-coil central rod domain, (i) plec284–1154  containing the plakin 
domain, (e) plec284–2532  containing the plakin domain and the rod domain, and (h) plec1390–2532 
containing solely the rod domain (figure 1). Numbers in superscript correspond to the amino 
acid residues of subclones. The African monkey kidney cell line COS-7 was grown in Dulbecco’s 
modified essential medium (DMEM) containing 10% (v/v) fetal calf serum. Cells were grown to 
70% confluence in 10-cm culture dishes and transiently transfected with 7.5 µg of cDNA by 
using Diethylaminoethyl-dextran.23 Cells were incubated with transfection medium for 3 hours, 
which was then replaced by DMEM medium. After 24 hours, this medium was replaced by 
DMEM containing 5 mM sodium butyrate. After another 24 hours incubation, the cells were 
washed twice with phosphate-buffered saline and directly lysed in Laemmli sample buffer. After 
heating at 95°C for 5 min the extracts were stored at –20°C until used.
figure 1. Schematic diagram of plectin 1a 
and the recombinant constructs used in the 
study. Underneath the full length plectin 1a 
the recombinant constructs are depicted, 
preceded by their corresponding character. 
C = COOH-terminal/intermediate filament 
binding domain (IFBD), N = N-terminal 
part of plectin 1a. On the right side of each 
construct the number of sera positive to 
each construct are shown. The cartoonized 
domains of plectin 1a as used in this figure 
are shown at the bottom. * Construct C was tested for 11 of the 12 sera.
immunoblot analysis 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and routine immunoblot 
analysis of patient sera on keratinocyte extracts was performed as described previously.16 
Immunoblot analysis with recombinant plectin constructs was done for all sera suspected of 
containing plectin autoantibodies and was performed as follows. After SDS-PAGE and transfer of 
the proteins on to nitrocellulose, the correct position of all constructs on the blots was identified 
with monoclonal 12CA5 that is directed against the HA-tag. For analysis of patient sera the blots 
were blocked in 1% milk in TBS (50 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris-
52
Chapter 3
HCl), pH 7.5 containing 500 mM NaCl) for 1 hour at room temperature. Incubation with patient 
serum was done overnight at 37 ºC with the serum diluted 1:300 in 1% milk in TBS in case IgG 
was detected and in 0.66% milk in TBS when IgA was present. The blots were washed three times 
for 5 minutes with TBS containing 0.05% Tween-20 (TTBS). Next, the blots were incubated for 
one hour at room temperature with AffiniPure mouse anti-human IgG, Fcγ-fragment-specific 
(Jackson ImmunoResearch, West Grove, PA, USA) 1:500 in TTBS or AffiniPure goat anti-human 
serum IgA, α-chain-specific (Jackson ImmunoResearch) 1:600 in TTBS. After another three 
5-minute washes with TTBS the blots were incubated for another hour with blotting grade 
alkaline phosphatase-conjugated goat anti-mouse IgG (H+L) (BioRad, Hercules, CA, USA) 1: 250 
in TTBS for detection of IgG, and with alkaline phosphatase-conjugated rabbit anti-goat IgA, Fc-
fragment-specific (Jackson ImmunoResearch) 1: 250 in TTBS for detecting IgA. Finally, the blot 
was developed with nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate in 1 M 
Tris-HCl buffer, pH 9.5 containing 100 mM NaCl and 10 mM MgCl2.
 
Affinity purification of serum antibodies 
From two sera we affinity-purified the antibodies that bound to the blot in a series of bands 
resembling a ladder and matching the binding pattern of the anti-plectin monoclonal 
antibody.22,24 As these purified antibodies were destined to prove by immunofluorescence 
that they were capable of binding back to human skin substrate, we specifically chose the IgA 
containing sera as background in immunofluorescence is generally lower for IgA than for IgG. 
Specific areas of the immunoblot were eluted using glycine-HCl, as described before.16 In brief, 
keratinocyte cell extract was separated by SDS-PAGE and electroblotted to 0.2 μm pore size 
nitrocellulose (Bio-Rad Laboratories, CA). Small vertical strips were excised and these were 
stained to identify the position where the patient antibodies bound. The corresponding area 
was then excised from the unstained blot. Similar-sized areas were cut from three other regions 
where no binding was observed, and served as controls for the elution process. The cut areas 
were incubated overnight in 1 ml of 1:20 diluted patient serum in TTBS at room temperature 
followed by two extensive washes with TTBS. Bound immunoglobulin was then eluted with 750 
μl of 20 mM sodium citrate, pH 3.2, and 0.01% ovalbumin during a four-minute incubation at 
room temperature, and then immediately neutralized by mixing in 150 μl of 2 M Tris-HCl, pH 
7.5. After overnight dialysis at 4ºC against phosphate buffered saline containing 0.01% Tween 
20, the antibodies were concentrated by ultrafiltration to 100 ul (Vivaspin concentrator 30,000 
MWCO PES, Vivascience, UK) and stored at –80ºC until used. 
immunofluorescence microscopy 
IIF microscopy was performed as previously described, using the following substrates: normal 
human skin, salt-split normal human skin, and plectin-deficient skin from a patient with 
epidermolysis bullosa simplex with muscular dystrophy (EBS-MD) homozygous for a null 
mutation in the plectin gene (c.G13187T, p.E1914X). 25Analysis of serum on a substrate that 
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misses the antigen of interest is also known as knock-out IF-analysis. 26  In brief, 4 μm thick 
cryostat sections were placed on microscope slides and air-dried before a fan for 15 minutes. 
Sections were washed in phosphate-buffered saline (PBS, 10 mM pH 7.3) and then incubated 
with patient serum for 30 minutes at room temperature. For salt-split skin analysis we used 
the serum at a 1:8 dilution, for knock-out analysis at a 1:4 dilution, and the affinity-purified 
antibodies were used undiluted. After thorough washing in PBS for 15 minutes, the sections were 
incubated for a further 30 min in fluorescein-conjugated Fcγ-specific goat F(ab’)2 anti-human 
IgA (Protos Immunoresearch, Burlingame, CA, USA) or fluorescein-conjugated Fcγ-specific goat 
F(ab’)2 anti-human IgG (Protos Immunoresearch, Burlingame, CA, USA) in PBS supplemented 
with 1% bovine serum albumin. After another 15 minutes of washing in PBS the sections were 
coverslipped under PBS-glycerol (1:1 v/v) and examined at 40 times magnification with a Leica 
DMRA fluorescence microscope (Leica Microsystems AG, Wetzlar, Germany). On each occasion, 
positive and negative serum controls were included. 
DIF microscopy was performed as described before.27 
resULts
Prevalence of plectin binding patient sera
Routine immunoblot analysis of the 282 patient sera revealed that 11 (3.9 %) displayed 
the characteristic high molecular weight “ladder” binding pattern (figure 2). The binding 
immunoglobulins were of the IgG isotype in 10 patients and of both the IgA and IgG isotype in 
one (patient #8). Nine of the eleven sera bound also to other bullous pemphigoid autoantigens, 
i.e. BP230, BP180 and LAD-1 by immunoblot (table I). In the table we included our control 
patient (#7) that has been described by us before as having both anti-plectin IgA and anti-type 
VII collagen IgA and IgG antibodies.22 
figure 2. Immunoblot analysis on keratinocyte extract shows 
binding of patient sera in a typical high molecular weight 
ladder pattern. 
Patient sera: lane 2, IgA patient #7 (1979 sample); lane 3, IgG 
patient #4; lane 4, IgG patient #5; lane 5, IgG patient #12 ; lane 
6, IgG patient #11. The same pattern was obtained with anti-
plectin monoclonal HD121 (lane 1). Additional binding to 
bullous pemphigoid antigens BP230 and/or BP180 is seen in 
lanes 3, 4 and 6. As substrate we used keratinocytes directly 
extracted with Laemmli sample buffer. The observed pattern 
depends on the detergent used for extraction: lane 7, Laemmli sample buffer extract; lane 8, Triton X-100 
extract. Both lanes were stained with monoclonal HD121. 
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the plectin binding sera show a typical “ladder”-pattern
The immunoblot binding pattern consists of at least ten different bands and is identical to the 
pattern seen with mouse monoclonal antibody HD121 that is specific to HD1/plectin (figure 2, 
lane 1).24 The ladder pattern was observed when cells were extracted with Laemlli sample buffer, 
which contains 2% SDS, while extraction with the mild detergent Triton-X-100 gave only one 
prominent higher molecular weight band (figure 2, lane 7-8). 
the blot-binding antibodies bind to human skin in a plectin distribution pattern
To investigate if the “ladder”-pattern IgA antibodies were indeed capable of binding to skin 
antigens, we eluted the bound antibodies of patients #7 and # 8. Both bound to the roof of 
salt-split skin (not shown). When incubated on a section of normal human skin IIF showed that 
the eluted immunoglobulin bound around the keratinocytes and along the epidermal BMZ (Fig. 
3a and c), in line with the distribution of plectin in epidermis in both hemidesmosomes and 
desmosomes.2,28,29 The staining is most prominent along the epidermal BMZ, and in IIF microscopy 
plectin staining along the epidermal BMZ may stand out whereas the intraepidermal staining 
may become weak on lower antibody concentrations (personal observation). In addition, 
binding was also observed around myocytes of the arrector pili muscles (figure 3e) in a pattern 
of dots and short lines at the cell periphery resembling the distribution pattern of plectin in 
smooth muscle tissue observed by Wiche et al. who stained urinary bladder smooth muscle cells 
with rabbit anti-plectin sera.30 No binding was seen with the control eluates (figure 3b, d and f ).
Plectin-deficient skin demonstrates absent or diminished binding of anti-plectin 
containing patient sera
If the circulating antibodies were directed to plectin only, they should not bind to skin or muscle 
of a patient with plectin-deficient EBS-MD. Indeed the whole serum IgA of patient #7 did not 
bind to the BMZ of plectin-deficient skin nor around myocytes of the arrector pili myocytes of 
plectin-deficient skin (figure 4a-d). When we incubated EBS-skin with whole serum of patient #8 
we observed severely decreased binding (figure 4e-j). The remaining weak signal therefore must 
be due to other antigen-specificity IgA serum antibodies being present, that were not detected 
by immunoblotting or IgA NC16A-ELISA as both these assays were negative.
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table i. Immunoblot and salt-split skin analysis of the anti-plectin sera. 








Plectin BP180 BP230 LAD-1
1
30/F IgG IgG Roof, IgG BP BP
2 78/F IgG IgG IgG Roof, IgG BP/DH BP
3 82/M IgG Roof, IgG PV/BP BP
4 88/M IgG IgG IgG IgG Roof, IgG BP/EBA BP




IgG, IgA Roof, IgG BP BP
7 81/F IgA Roof, IgA LAD EBA
8 83/F IgG, IgA Roof, IgA LAD LAD
9 81/M IgG IgG IgG Roof, IgG BP/PV BP
10 64/M IgG IgG Roof, IgG BP BP
11 57/F IgG IgG Roof, IgG BP BP
12 1/F IgG IgA Roof, IgA LAD LAD
Patient #7 has been described by us before as having additional antibodies to type VII  collagen.22 BP = 
bullous pemphigoid, DH = dermatitis herpetiformis, PV = pemphigus vulgaris, EBA = epidermolysis bullosa 
acquisita, LAD = linear IgA dermatosis.
in vivo depositions in hair muscle tissue and staining along the BmZ of muscle cells
Muscle cells contain plectin but not BP230, BP180 or LAD-1. We therefore looked for evidence 
of IgG or IgA deposition in hair muscle. Only one of our patient biopsies of perilesional skin 
(patient #7) contained a hair muscle. DIF of a cross-section of this biopsy showed a fine dotted 
granular pattern (figure 3g). We do not have any evidence that this deposition is due to anti-
plectin antibodies, but we never observed any such deposition before in hair muscle. 
Binding of anti-plectin antibodies to recombinant plectin domains
All suspected anti-plectin sera were tested for binding of antibodies to recombinant fragments 
of plectin (figure 1). The antibodies from eleven patients reacted with the central coiled-coil 
rod domain (fragment Plec1390-2532). Two of the sera also contained antibodies that bound to the 
actin-binding domain (fragment Plec1-339; table II). None of the sera bound the plakin domain 
(fragment Plec284-1154). The serum of one patient was negative for all constructs used and may 
have specificity to epitopes not present in the used recombinant fragments (patient #5). Control 
sera from BP230 or BP180 positive pemphigoid patients did not react with the constructs (not 
shown). We also tested sera from 4 PNP patients, as plectin is reported in the literature as a PNP 
autoantigen,17,18,31 but none of our sera reacted with any of the recombinant plectin domains nor 
with native plectin from keratinocyte cell extracts (not shown). 
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1 - - - + + + -
2 + + + + + + -
3 - - - + + + -
4 - - - + + + -
5 - - - - - - -
6 - - - + + + -
7 - - - + + + -
8 - - - +/- +/- + -
9 - - - +/- +/- + -
10 - - - + - + -
11 + + n.d. + +/- + -
12 - - - - - +/- -
Patients #1-6 and #9-12 IgG, patients #7 and #8 IgA.
+ strong positive, +/- weak positive, - negative, n.d. not done
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figure 3. IgA affinity-purified antibodies bind back to human skin 
in a plectin-like pattern.
IIF of affinity-purified IgA (patient #7, 1985 sample) on normal skin 
substrate shows linear BMZ and intercellular staining of epidermal 
(a) and hair follicle keratinocytes (c), and also around the arrector pili 
myocytes (e). No binding was seen with the control eluate; epidermal 
(b) and hair follicle keratinocytes (d), and arrector pili myocytes (f ). 
Scale bar is 10 mm. DIF of oblique cross-section of smooth muscle 
arrector pili tissue (patient #7) shows in vivo deposition of IgA in a 
fine dotted granular pattern (g). Scale bar is 10 mm.
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figure 4. Absent or diminished binding of anti-plectin serum IgA to plectin-deficient EBS-MD skin.
IIF of whole serum of patient #7 (a and c with 1985 sample, b and d with 1979 sample) on EBS-MD skin 
(a,b) and normal skin (c,d). Note that perinuclear binding is not lost on EBS-MD skin (a). The myocytes of 
the arrector pili muscle of plectin-deficient skin do not bind IgA (b) in contrast to those of control skin (d). 
Scale bar is 10 mm. IIF of normal human control serum (e,h), whole serum of patient #8 (f,i) and serum from 
a juvenile LAD patient (g,j) on EBS-MD skin (e,f,g) and normal skin (h,i,j). The IgA staining along the BMZ is 
severely diminished on EBS-MD substrate for the anti-plectin serum (compare f and i) while the serum of the 
juvenile LAD patient, that had IgA antibodies to the LAD-1 antigen, does bind to the EBS-MD substrate with 
similar intensity as to normal skin (compare g and j). Scale bar is 25 mm.
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DisCUssion
The experiments described here demonstrated undoubtedly the existence of anti-plectin 
autoantibodies in patients with subepidermal blistering diseases. Serum immunoblot staining 
patterns were identical to that of the monoclonal anti-plectin; affinity-purified antibodies stained 
skin - and muscle - in a plectin distribution pattern; binding of whole sera to plectin-deficient 
skin was absent or diminished; and sera specifically bound recombinant plectin constructs. The 
finding of immunodepositions on arrector pili muscle by DIF is also a sign for the existence of 
anti-plectin antibodies.
In a series of 282 consecutive patients with subepidermal blistering diseases we found a 
prevalence of 3.9 % (11/282) which is similar to the one out of sixteen reported before by Laffitte 
et al.21 The patient  with EBA, used as a positive control, was not included in the calculation of 
the prevalence as the sera of this patient dated back to before the inclusion period. We had 
four sera of her available that were collected over a period of nine years and all these contained 
anti-plectin IgA antibodies. This one particular patient proved the diagnostic potential of new 
laboratory assays as immunoblot and served as a trigger for the current study. In PNP the 
reported prevalence seems much higher with reported incidence figures of 81% (13/16) by 
immunoprecipitation and 82% (23/28) by immunoblot,18,31 however we could not confirm these 
figures as our four PNP patients reacted negative by immunoblot.
In all but one case we also demonstrated that concomitant antibodies to other antigens were 
present, in nine cases these were the classical BP antigens, in one case the EBA antigen (#7) 
and in one case an unidentifiable antigen (#8). The one patient (#3) that seemed to have only 
anti-plectin antibodies appeared to have anti-BP230 antibodies two years later (not shown). 
Due to this multi-antigen response the direct pathogenicity and the clinical manifestation of 
the anti-plectin antibodies cannot be determined. This ‘more than one antigen’ response is 
common to BP where IgG reactions to both BP230 and BP180 and/or LAD-1 are commonly 
seen16 and is explained by ‘epitope spreading’, which is a secondary autoimmune response to 
other hemidesmosomal antigens during a chronic autoimmune or inflammatory response.32,33 
In this regard, plectin, being part of the hemidesmosome, could be exposed to the immune 
system during a primary inflammatory response to BP230 or BP180. In line with such vision is 
that all but one of our patients had antibodies to other antigens.
The reactivity of the patient sera with the recombinant plectin constructs not only confirmed 
their plectin-specificity but also allowed partial mapping of the recognized epitopes. Eleven 
out of twelve sera (92%) bound to the coiled-coil rod domain, implying that this rod domain 
harbours one or more major epitopes. Two sera (17%) also bound to the actin-binding domain, 
implying that this is another but minor antigenic site. The plakin domain did not contain 
epitopes. One serum reacted strongly with the keratinocyte extract but did not react with any 
of the recombinant fragments. This may be due to post-translational modifications not present 
on the recombinant constructs, but it is also conceivable that the epitope here is present on 
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the COOH-terminal intermediate filament binding domain (IFBD). As the IFBD was not present 
in our constructs we cannot exclude that the other sera also might recognize epitopes on this 
domain. BP230, a major bullous pemphigoid antigen and also a plakin family member, has a 
similar structure containing both a rod domain and an IFBD domain. Skaria et al., using COS7 
cells produced BP230 fragments, found multiple antigenic reactive sites on BP230 mostly 
situated (84% of the sera) on the IFBD, but not more than 36% of the sera bound the rod 
domain.34 Therefore the plectin rod domain may be more immunoreactive than the BP230 rod 
domain, although the immunoreactivity of the BP230 rod domain may be underestimated 
as Skaria et al. missed a mid-rod 300 amino acid sequence (11.3 %) in their constructs. Other 
plakin family members desmoplakin, envoplakin and periplakin have also been recognized as 
autoantigens. Desmoplakin, as BP230, was demonstrated to harbour major epitopes on the 
COOH-terminal part. Periplakin and envoplakin are antigens in PNP, and sera of these patients 
were demonstrated to bind to multiple epitopes, not only COOH-terminal but distributed over 
the whole of both proteins including the plakin domain.35-39
Earlier studies had demonstrated either a ladder pattern or one band for plectin.18,21,40 The 
explanation for this inconsistency is most likely the nature of the detergent used: the heavily 
denaturing SDS will dissolve entire protein complexes where the non-ionic Triton-X-100 will 
only extract loosely bound protein. We agree with McLean et al. that is unlikely that the lower 
molecular weight bands arise from the higher molecular weight bands trough proteolytic 
degradation.40 We observed the exact same pattern irrespective of whether we extracted the 
cells immediately in Laemlli sample buffer containing an additional mix of proteolytic inhibitors, 
or left them first for 15 minutes lysed in water without proteolytic inhibitors (not shown). Also 
extracts prepared from another source -human epidermis- gave a similar pattern (not shown). 
The two most plausible explanations for the multiple bands are either a high cellular turnover of 
plectin, visible as a series of degraded fragments, or the presence of different isoforms encoded 
for by alternative spliced transcripts. The latter idea is supported by molecular analyses of 
human, mouse and rat cDNA that have already demonstrated up to 16 different transcripts.3,41,42 
Also rodless isoforms have been identified in rat and man of which the human form was visible 
as a 360 kDa minor protein band next to the 520 kDa full-length protein.43,44 
Our clinical data are limited to a retrospective review of case notes. Reviewing the patient files 
did not reveal other obvious clinical manifestations than blisters. We also contacted the physicians 
who treated the patients at the time of serum collection but none of them remembered any 
specific clinical aberrations unusual for bullous disease. Close examination of new patients that 
present with anti-plectin antibodies might eventually reveal unexpected or unusual features. 
The following final conclusions can be drawn from the experiments described in this study. 
First, plectin indeed has to be grouped with the hemidesmosomal proteins that may become 
autoantigenic targets in immunobullous diseases. Second, its rod domain harbours one or 
more immunodominant epitopes. Third, based on its prevalence it is a relatively minor antigen 
compared to BP230 and BP180. 
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IgG antibodies to BP180 in a subset of oral lichen planus patients
Lichen planus is a chronic inflammatory disease of skin, and oral and genital mucous membranes. 
The histopathology of oral lichen planus (OLP) is quite uniform consisting of a prominent 
inflammatory band-like lymphocytic infiltrate, normal maturation of the epithelium, a saw-
toothed appearance of rete ridges, civatte or colloid bodies, hyperkeratosis, and liquefactive 
degeneration of basal epithelial cells. Direct immunofluorescence microscopy (DIF) shows 
shaggy deposits of fibrin and fibrinogen along the epidermal basal membrane zone (BMZ). The 
band-like T-cell infiltrate that concentrates underneath the basal keratinocytes suggests that 
the pathogenesis takes place around the BMZ. In the infiltrate, especially the cells underneath 
the BMZ, the CD8+ T-cells dominate, with CD4+ T-cells somewhat lower in the lamina propria. A 
Th1 immune response to promote CD8+ cytotoxic T-cell activity was suggested in OLP. Antigen 
presentations to both CD8+ and CD4+ T cells can generate CD8+ cytotoxic T-cell activity.1 
In our laboratory sera from patients suffering from inflammatory lesions of the oral mucosa 
are routineously screened for pemphigus or pemphigoid antibodies. We then noticed that 
some patients with proven OLP had IgG autoantibodies to BP180 at low titer. Consequently, 
we analysed the prevalence of these autoantibodies in a larger series of OLP patients. From 
each patient one oral biopsy was collected for histopathological analysis and one for DIF. Also 
a serum sample was taken for immunoblot and ELISA analyses. From 2002 to 2004 we included 
47 consecutive patients with OLP (proven by clinical presentation and histopathology).2,3 DIF 
of the mucosal biopsies showed in all cases shaggy deposits of fibrin and fibrinogen (1+ to 3+) 
along the epidermal BMZ, but no IgA, IgG or IgM, neither along the BMZ nor intraepidermal, in 
line with the diagnosis OLP.4
For immunoblotting we used cellular extracts of cultured normal keratinocytes and of cultured 
BP180-deficient keratinocytes from a patient with generalized atrophic benign epidermolysis 
bullosa, baculovirus produced recombinant full-length-BP180 and bacterial recombinant 
NC16A substrate. 
Immunoblotting with normal keratinocytes extract showed for 8 out of 47 (17%) OLP patient 
sera IgG autoantibodies that bound to a protein at the position of BP180. In our laboratory sera 
from patients other than suffering from pemphigoid only sporadically demonstrate unexplained 
anti-BP180 antibodies (< 1%).  Although the intensity of the staining was weak it was clearly 
present (figure 1A). To confirm that the binding was directed to BP180, the immunoblotting was 
repeated with the BP180-deficient cell substrate. Now no 180 kDa band was observed, indicating 
that the sera indeed reacted to BP180 (Fig. 1B). For further proof the eight anti-BP180 sera were 
tested for binding to recombinant BP180. Five of them also reacted with the recombinant full-
length BP180 (figure 2A) and of these five, two bound recombinant NC16A (figure 2B). 
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figure 1. Immunoblot on normal keratinocyte cell 
extract and BP180 deficient keratinocyte cell extract. 
A. All 8 OLP sera showed a band at the 180-kDa 
position (lanes 2-9). Lane 1: Bullous pemphigoid 
control serum binding BP180 and BP230. Lanes 10-
13: Negative control sera of  pemphigus vulgaris oris 
patients. No binding to other proteins was observed. 
Immunoblotting for IgA antibodies to this 180 kDa 
protein was negative and no other bands were 
observed.  
B. Cell extract of BP180-deficient keratinocytes was 
negative for the 180 kDa band (lanes 2-9). Lane 
1: same control as in A. Immunoblotting with the 
cellular extracts was performed as described previously.6
The anti-BP180 titer of the OLP sera is low. On immunoblot serial dilutions of anti-BP180 
bullous pemphigoid (BP) sera and OLP sera demonstrated that the OLP signal became lost 
at approximately 100 times lower dilution than the BP sera (not shown). Other tests were in 
accordance with this low titer: no IgG deposits were seen in DIF of skin biopsies, in serum 
immunofluorescence no binding to the BMZ of monkey esophagus could be detected while on 
the more sensitive salt-split skin substrate only one serum was positive (1+) in the roof of the 
split with no detectable binding in the other cases, and in a NC16A ELISA all sera reacted below 
the cut-off value of the test. Immunoblot is, more than ELISA or immunofluorescence, a very 
sensitive technique that remains positive when other techniques reach their detection limits.
figure 2. Immunoblot on recombinant full-length 
BP180 (and the recombinant NC16A domain). 
A. Five out of eight patient sera reacted with the 
recombinant full-length BP180 (lanes 2-4, 7 and 9). 
Lane 1: anti-RGSH4 fusion protein. Lanes 10 and 11: 
healthy control sera. 
B. Two of these 5 sera (lanes 7 and 9) also bound 
recombinant NC16A. Lane 1: anti-Strep tag, lane 12: 
anti-RGSH4 fusion protein. Lanes 10 and 11: healthy 
control sera. None of the 20 control sera reacted with 
the recombinant proteins. Lanes 2-9 correspond to 
lanes 2-9 from figure 2A and to lanes 2-9 from figure 
1. Recombinant full-length BP180 was obtained from 
baculovirus infected Sf21 insect cells as described 
previously.7 The recombinant NC16A fragment 
was expressed as a GST fusion protein in E. coli TG1 and was purified by glutathione agarose affinity 
chromatography .8
71
IgG antibodies to BP180 in a subset of oral lichen planus patients
Five of the eight sera were positive for the recombinant full-length BP180 from insect cells. 
That not all eight patients reacted with recombinant BP180 may be due to incorrect folding 
or incomplete glycolysation of the recombinant protein. Two of the five sera that reacted with 
recombinant full-length BP180 also bound the recombinant NC16A domain. While the NC16A 
domain is immunodominant in BP, in mucous membrane pemphigoid (MMP) also the carboxy-
terminal domain is targeted. Similarly, in OLP other epitopes than NC16A may be targeted, as we 
could only demonstrate immunoblot binding to the NC16A for two of the eight cases. 
BP180 is a transmembrane hemidesmosomal molecule, with an elongated ectodomain long 
enough to overspan the lamina lucida. It is the most prominent autoimmune target in the 
blistering diseases bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucous 
membrane pemphigoid and in lichen planus pemphigoides. What aspects make BP180 to such 
a dominant autoantigen is unknown.
The current hypothesis on OLP pathogenesis is that cytotoxic CD8+ T cells, assisted by CD4+ 
T-cells, destroy basal keratinocytes through triggering apoptosis. It is currently unknown 
whether activation of both CD8+ T-cells and CD4+ T-cells occurs through the same antigen or 
through two different antigens.1 It is also unknown if the antigen is a self-protein making OLP 
to a true autoimmune disease, although OLP appears to have many features that support such 
vision. The development of antibodies might be a secondary, humoral, response to an antigen, 
in this case BP180, which becomes exposed in the chronic inflammatory process caused by the 
primary cellular response. Such a process is known as epitope spreading. Vice versa, humoral 
T-cell activity may start the pathogenesis before cytotoxic CD8+ T cells get the advantage.
Recently, Cooper et al. described BMZ-binding IgG antibodies in 61% of patients with clinical 
erosive lichen planus of the vulva.5 This IgG was chiefly directed to BP180. In serum laboratory 
diagnosis such observations would normally coin the diagnosis of mucous membrane 
pemphigoid. Biopsies did not demonstrate BMZ-deposits of IgG. Their biopsies, however, had 
been taken from lesional skin, and thus were at risk for becoming negative for potential Ig 
deposits as these can be destroyed in the inflammatory process. Also the fibrinogen deposits, 
characteristic to lichen planus lesions, were absent in all their biopsies. All our eight patients had 
the shaggy deposits of fibrin/fibrinogen along the BMZ typically encountered with lichenoid 
infiltrates. Nevertheless it is striking that they, as we, found BP180 autoantibodies in patients 
with lichen planus histology.
This study showed that low circulating anti-BP180 IgG titers of unknown function exist in a 
minority (17%) of OLP patients. The presence of anti-BP180 antibodies in a subgroup of OLP 
patients might be considered a connecting element to the IgG mediated pemphigoid diseases 
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Mucous membrane pemphigoid (MMP) encompasses a group of chronic subepithelial 
autoimmune bullous diseases that predominantly affect the mucous membranes with potential 
scar formation. The autoimmune targets are heterogeneous, and are all components of the 
epidermal basement membrane zone (BMZ). Patients with anti-epiligrin cicatricial pemphigoid 
(AECP) have serum antibodies against laminin 5 (α3β3γ2), formerly known as epiligrin.1 Here, 
we report a unique case of AECP with skin blistering without involvement of the mucous 
membranes. 
A 46–year-old Moluccan women presented with generalised skin blistering. She had no history 
of lesions in the mouth, throat, nose, eyes, or vagina. When the skin blistering started, she had 
been taking the oral anticonceptives for years. After the onset of the skin blistering, she received 
aciclovir tablets for five consecutive days, without improvement of the blistering. Physical 
examination revealed generalised tense bullae on erythematous base, erosions, crusts, and 
scale formation. Mucous membranes were not involved. The blistering  was widespread and 
lesions spread centrifugally from involved skin to skin that had not been involved previously. 
This wave of blistering healed with hypopigmentation (figure 1). Previously affected skin did 
not blister again. 
figure 1. Centrifugal spread of circinary 
vesicles leaving hypopigmentated skin 
behind.
Histopathology showed a subepidermal blister with an inflammatory infiltrate in the upper 
dermis composed of lymphocytes and eosinophilic leukocytes. Direct immunofluorescence 
(DIF) of non-lesional skin before the blister front showed a linear and n-serrated pattern of IgG 
(2+/3+) (figure 2A), C3c (1+) and to a lesser extent IgA and IgM along the epidermal BMZ. DIF of 
healed skin behind the blister front revealed much less IgG (- /1+) and C3 (1+) deposition (figure 
2B).
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figure 2. DIF of non-lesional skin of the upper leg prior to blistering reveales IgG depositions (2+/3+) in an 
n-serrated pattern along the epidermal BMZ (A). DIF of healed skin, behind the wave of vesicles, shows much 
less IgG depostion (-/1+) along the epidermal BMZ (B).
Indirect immunofluorescence microscopy on monkey oesophagus showed IgG antibodies at 
the epidermal BMZ (titer 1/10). Circulating IgG autoantibodies bound to the dermal side of 1M 
NaCl split human skin.  Immunoblotting on human keratinocyte extracellular matrix using the 
patient’s serum revealed binding of IgG antibodies to bands of 200 and 165 kD corresponding 
to the unprocessed and processed α3 chains of laminin 5, confirming the diagnosis of AECP. No 
other antigens were identified by the patient’s serum.
A final diagnosis of anti-epiligrin cicatricial pemphigoid (AECP, anti-laminin 5 pemphigoid) 
without mucous membrane involvement was made. A chest X-ray and laboratory tests did not 
reveal any malignancies. Treatment with oral dexamethasone 300 mg on three consecutive days 
per month over 12 months, prednisolone 30 mg daily tapered and withdrawn over 9 months, 
and azathioprine 3 mg/kg daily, resulted in complete and persistent remission of the cutaneous 
lesions. Azathioprine was tapered and withdrawn one year after complete remission. Until 
now, the patient has been free of disease for three years with only a slight postinflammatory 
hyperpigmentation.
Clinically, patients with MMP present with severe vesicles, erosions and crusts on mucous 
membranes, typically affecting the oral cavity and eyes, but it also may affect the nasal, 
pharyngeal, laryngeal, oesophageal and/or anogenital regions.1 When lesions occur on the skin, 
the scalp, face and/or upper trunk are predilection sites.2 In our patient however, the blistering 
was generalised, while the mucous membranes remained unaffected. MMP is rare, with an 
estimated  annual incidence of 1.16 and 0.87 cases per million as reported for the population 
in France and Germany, respectively.3;4 AECP is estimated to comprise 5% to 20% of all these 
MMP cases.2 Egan et al. described that in a cohort of 35 AECP patients 100% of the patients had 
mucous membrane involvement and 86% had mild to moderate skin involvement.2 To the best 
of our knowledge, this is the first report of a case with AECP with exclusive cutaneous lesions 
without involvement of the mucous membranes.
Anti-epiligrin antibodies bind exclusively to the dermal side of salt split skin, as do antibodies 
to collagen type VII in case of epidermolysis bullosa acquisita (EBA). Differentiation between 
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EBA and AECP is possible with immunoblot. An important clue diagnosis from routine DIF is an 
n-serrated pattern in AECP, whereas EBA will show an u-serrated pattern.5
This case illustrates skin involvement of an AECP patient with centrifugal ‘wave-like’ progression 
of blister formation. DIF showed a marked reduction of IgG deposition between the skin in front 
of and behind the wave of blisters. We believe that the direction of blister spread is propelled 
by the difference of IgG load along the epidermal BMZ. The inflammatory blistering process 
consumes immunodeposits. When the skin heals after blistering subsequent loading of the 
epidermal BMZ with new immunodepositions from the circulation is apparently slow.
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Background: Objective was to estimate frequency of epidermolysis bullosa acquisita and 
bullous systemic lupus erythematosus among patients with subepidermal autoimmune bullous 
disease, and to correlate the isotype of in vivo antibody depositions to the clinical phenotype.
methods: Patients with epidermolysis bullosa acquisita or bullous systemic lupus erythematosus 
were systematically identified using serration pattern analysis of immunoglobulin depositions 
along the epidermal basement membrane zone by direct immunofluorescence microscopy. 
Correlation of the clinical phenotype to the isotype of the in vivo antibody depositions was 
investigated for 38 prospective and retrospective cases.  
results: The frequency of epidermolysis bullosa acquisita or bullous systemic lupus 
erythematosus was 5.5% (n=20), defined by u-serration pattern, in a prospective cohort of 364 
patients with subepidermal autoimmune bullous disease, and would reach only 1.9% (n=7) 
when serological reactivity was the only criterium. The clinical phenotype of epidermolysis 
bullosa acquisita was mechanobullous in 14 (37%) and inflammatory in 24 (63%) of the patients. 
The mechanobullous phenotype of epidermolysis bullosa acquisita was found in 67% of the 
pure IgG cases, in 33% of the mixed IgG/IgA cases and in only 9% of the pure IgA cases. The 
inflammatory phenotype was found in 33% of the pure IgG cases, in 67% of the mixed IgG/IgA 
cases and in 91% of the pure IgA cases. Mucous membrane involvement was present in 22 (58%) 
patients, and did neither correlate with IgG or IgA depositions, nor with a mechanobullous (64%) 
or inflammatory (54%) phenotype. 
Conclusions Epidermolysis bullosa acquisita comprises one in twenty patients with 
subepidermal autoimmune bullous disease. The clinical phenotype is in more than half of the 
cases inflammatory, thus mimicking other subepidermal autoimmune bullous diseases, i.g. 
bullous pemphigoid, mucous membrane pemphigoid, or linear IgA disease. Pure IgG-mediated 
cases were associated with the mechanobullous phenotype, whereas pure IgA-mediated 
cases were more found in the inflammatory phenotype. The yield of diagnosed epidermolysis 
bullosa acquisita cases almost triples when serration pattern analysis is used by direct 
immunofluorescence microscopy on skin biopsy. 
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introDUCtion
Epidermolysis bullosa acquisita (EBA) is a subepidermal autoimmune bullous disease (sAIBD) 
characterized by autoreactivity to type VII collagen in the anchoring fibrils located in the 
epidermal basement membrane zone (BMZ).1
EBA is a heterogeneous disease that may be characterized by either an inflammatory or a 
mechanobullous clinical phenotype. Bullous systemic lupus erythematosus (bSLE) is a bullous 
variant of systemic lupus erythematosus with autoantibodies against type VII collagen.2,3 
Diagnose can be made by indirect immunofluorescence microscopy (IIF) performed on 1 M NaCl-
split skin (SSS) substrate showing binding of antibodies to the dermal side (floor) of the blister 
and by immunoblot analysis revealing immunoglobulin binding to the 290 kDa antigen.1,4,5 In 
serological negative cases direct immunofluorescence (DIF) on sodium chloride-separated skin 
biopsy might reveal the diagnosis.6 More simply, the diagnosis can be reached through serration 
pattern analysis by DIF revealing linear u-serrated immunodepositions along the epidermal BMZ, 
which proves for the diagnosis EBA or bSLE.7-9 The u-serration pattern represents immunoglobulin 
depositions in upstanding arms (‘grass’) of the sublamina densa zone between the rootlets of 
the basal keratinocytes. This pattern is specific for EBA or bSLE since type VII collagen is the 
solely identified autoantigen located in the sublamina densa zone.7,9,10 The autoantigens in all 
other sAIBD are located in or above the lamina densa, and immunodepositions will display 
in n-serrated pattern following the rootlets of the basal keratinocytes.7The n-serrated sAIBD 
comprise all forms of pemphigoid including anti-laminin-332 mucous membrane and anti-
laminin-γ1 (p200) pemphigoid, although in the latter two serum antibodies bind to the floor of 
salt-split skin. 
The main autoantibody isotype in EBA is IgG, but deposits of IgA, IgM, complement and 
properdin may also be found along the epidermal BMZ.11,12
The classic mechanobullous phenotype mimics dystrophic epidermolysis bullosa hereditaria, 
while mild cases look like acral blistering of porphyria cutanea tarda, that heal with atrophic 
scarring, milia and hypo- or hyperpigmentation.13 Scalp, neck and shoulders involvement occurs 
in 20% and leads to extensive non-healing erosions with scarring, reminiscent of Brunsting-
Perry pemphigoid.14 The inflammatory phenotype presents with widespread vesicles and bullae 
involving intertriginous and flexural areas that heal with no or few milia without scars. This 
phenotype comprises a bullous pemphigoid-like presentation with a widespread inflammatory 
vesicubullous eruption involving trunk and extremities or skin folds, and a presentation with 
predominantly mucosal involvement reminiscent of mucous membrane pemphigoid with scars 
on the mucosal surfaces.15,16 Another presentation with grouped circinary vesicles and arciform 
erythema resembles linear IgA disease.17 Patients with bullae and SLE present either with acute 
widespread inflammatory blistering with a striking therapeutic response to Dapsone (bSLE) or, 
less often, as the chronic mechanobullous phenotype with a lesser response to first-line therapy 
(classic mechanobullous-EBA with SLE).18
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Using the serration pattern analysis by DIF, we identified the largest series of EBA/bSLE patients 
ever reported before. Aim of this study was to estimate the frequency of EBA within the group of 
sAIBD using u-serration pattern analysis, to inventarize the clinical phenotypes and to correlate 
them to the in vivo immune depositions as found by DIF.
mAteriALs & metHoDs
Tissue samples of sAIBD patients as witnessed by DIF showing a linear deposition along the BMZ 
were collected in our national reference center for blistering diseases in the Netherlands. The 
frequency of EBA was estimated from all consequetive biopsies of 364 new patients with sAIBD 
collected between 2002 to 2008 in our center. The diagnosis EBA was based on the following 
criteria: 7,19
1. patient with mucosal and/or cutaneous disease, and,
2. u-serrated pattern of linear immunodeposits along the epidermal BMZ by DIF of skin tissue 
for IgG and/or IgA, and/or,
3. autoantibodies to type VII collagen established by dermal staining in IIF on SSS substrate 
and reactivity to 290 kDa band by immunoblot on dermal extract. 
Recognition of a u-serration pattern is sufficient for diagnosis, but when only serum is available 
the floor staining pattern in SSS should pair with anti-type VII collagen antibodies as detected by 
immunoblot, to exclude anti-laminin-332 or anti-laminin γ1 pemphigoid.
In addition, a diagnosis of SLE was based upon American Rheumatism Association (ARA) criteria.20 
Patients seen from before 2002 were included on base of EBA specific serological reactivity, 
and the u-serration pattern retrospectively analysed by DIF of the banked biopsy. In all cases 
where serum and/or biopsies were available, patient files with additional photodocumentation 
were studied. Clinical presentation was classified into mechanobullous and inflammatory EBA/
bSLE.2,13 The mechanobullous was further split into classic generalized mechanobullous (cMB), 
and localized Brunsting Perry pemphigoid (BrPr)-like EBA. The inflammatory phenotype was 
split in bullous pemphigoid (BP)-like, mucous membrane pempigoid (MMP)-like, and vesicular 
pemphigoid (VP)-like EBA/bSLE.14-17
Skin specimens and serum samples were all collected in our laboratory. DIF for fibrin, IgA, IgM, 
IgG and C3c, and IIF on SSS for IgG and IgA was performed as described before.21 Staining 
intensities were graded from 1+ to 4+. Histopathological examination on routine biopsies were 
assessed for defining the blister infiltrate. SDS PAGE and routine immunoblot analysis of patient 
sera on dermal extract were performed as described.22,22 We further classified the patients 
according to the immunoglobulin isotype(s) (IgG, IgA, mixed IgA/IgG) present in BMZ deposits 
and/or serological reactivity. 
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figure 1. Atlas of the clinical phenotypes of EBA.
Thirty-eight patients with EBA and bSLE were immunologically subtyped according to the patients antibody 
isotype(s) (IgG, IgA or mixed IgG/IgA) observed by DIF/IIF. The subtypes were then further defined into 
subgroups according to the patients symptoms. From the upper and lower left panel to the right are clinical 
pictures of patients shown: a-b; the bullous pemphigoid-like subtype of inflammatory IgA-EBA (patient 
#14), c-d; the vesicular pemphigoid-like subtype of inflammatory IgA-EBA (patient #18), e-f; the mucous 
membrane pemphigoid-like subtype of inflammatory mixed IgA/IgG-EBA (patient #27), g-h; the Brunsting 
Perry pemphigoid-like subtype of mechanobullous IgG-EBA (patient#7), i-j; the classic generalized subtype 
of mechanobullous mixed IgA/IgG-EBA and SLE (patient#36) and k-l; the classic generalized subtype of 
mechanobullous IgG-EBA (patient#6). 
resULts
The number of EBA/bSLE among 364 prospective cases with a sAIBD in our database was 20 
(5.5%) using DIF serration pattern analysis, whereas the yield of EBA diagnosis would be limited 
to seven sAIBD cases (1.9%) if only one positive serological criterium (at least SSS IIF floor or IB 
290 kDa) had been used (Table I, patients 13, 14, 17, 22, 24, 35, 36 and Table II). 



















DIF u-serration N (%) 20 (100%) 7 (100%) 13 (100%) 6 (100%) 7 (100%) 7 (100%)
SSS IIF: N (%) 7 (35%) 4 (57%) 3 (23%) 0 (0%) 4 (57%) 3 (43%)
Immunoblot N (%) 4 (20%) 3 (43%) 1 (8%) 0 (0%) 1 (14%) 3 (43%)
Direct immunofluorescence (DIF) u-serration pattern, floor staining salt-split skin indirect immuno fluo-




table i. General, clinical and immunological characteristics of EBA patients studied
#/sex/age P/r eBA/bsLe  
subtype
mm isotype Dif serration
pattern  
(n or u)










1/F/35 P MB-cMB EBA - G G+ u - -
2/F/47 P MB-cMB EBA - G G3+ C3c+ u - -
3/F/46 R MB-cMB EBA + G G3+ C3c+ u G3+ +
4/M/43 R MB-cMB EBA + G G4+ C3c+ u G2+ +
5/M/29 R MB-cMB EBA + G G2+ u G+ +
6/M/67 R MB-cMB EBA + G G2+ u G3+ -
7/F/75 R MB-BrPr EBA + G G4+ C3c3+ u G+ +
8/F/62 P Inf-BP  EBA - G G2+ u - -
9/F/61 P Inf-BP EBA - G G3+ C3c2+ u - -
10/F/64¶ R Inf-BP EBA + G G4+ C3c3+ u G3+ +
11/M/72 P Inf-BP EBA - G G2+ C3c3+ u - -
12/F/31* P MB-cMB-EBA+SLE - G G3+ M2+ C3c+ u - -
13/F/63 P MB-cMB EBA - A A3+ u A2+ -
14/F/79 P Inf-BP EBA + A A3+ u A+ -
15/M/29 P Inf-VP EBA - A A2+ u - -
16/F/42 P Inf-VP EBA - A A2+ C3c+ u - -
17/F/69 P Inf-VP EBA + A A3+ u A2+ -
18/F/67 P Inf-VP EBA + A A3+ C3c2+ u - -
19/M/60 R Inf-VP EBA - A A3+ C3c+ u A2+ -
20/F/55 R Inf-VP EBA - A A3+ C3c2+ u A2+ -
21/F/53 R Inf-VP EBA + A A3+ M2+ u - -
22/F/53 P Inf-BP EBA + A A3+ C3c3+ u A+ -
23/F/30 Φ R Inf-VP EBA + A A3+ M+ C3c+ u A2+ -
24/F/39 P MB-cMB EBA + A,G A3+ G4+ M+ C3c3+ u A2+G3+ + +
25/M/41 R MB-cMB EBA + A,G A2+ G3+ C3c2+ u A+G+ + -
26/F/59 R MB-cMB EBA - A,G G4+ A+ M2+ C3c2+ u G3+ + -
27/F/83 ‡ R Inf-MMP EBA + A,G G3+ A2+ C3c3+ undefined G3+ + -
28/F/21 P Inf-MMP EBA + A,G A+ G+ M2+ u - - -
29/M/67¥ P Inf-VP EBA + A,G A2+ G+ M3+ C3c2+ u - - -
30/M/69 P Inf-BP EBA + A,G A3+ G+ C3c2+ u - - -
31/F/53 R Inf-BP EBA - A,G G2+ A2+ u - - -
32/M/13 R Inf-BP EBA - A,G G3+ A+ M2+ C3c+ u G3+ + +
33/F/79 ∑ R Inf-BP EBA + A,G G3+ A3+ M2+ C3c2+ u - - -
34/F/17 R Inf-BP EBA - A,G NA NA G3+A3+ + -
35/M/31* P MB-cMB-EBA+SLE + A,G G3+ A+ C3c+ u G3+ + -
36/F/19* P MB-cMB-EBA+SLE + A,G G3+ A2+ C3c2+ u G2+ - -
37/F/34 R Inf-BP-bSLE + A,G A4+ G+ M2+ u A2+ - +
38/M/76 P Inf-Pru EBA - A,G A+ G+ M3+ u - - -
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EBA epidermolysis bullosa acquisita, bSLE bullous systemic lupus erythematosus, MB mechanobullous 
phenotype, cMB classic mechanobullous, BrPr Brunsting Perry-like, Inf inflammatory phenotype, BP bullous 
pemphigoid-like, VP vesicular pemphigoid-like, MMP mucous membrane pemphigoid-like, Pru pruritus-
like.
M male, F female, P prospectively found cases, R retrospectively found cases, a.i. antibody isotype, MM 
mucous membrane involvement, + positive, - negative, NA not available.
‡Mucous membrane biopsy not suitable for serration pattern analysis. Presence of type VII collagen IgG 
was confirmed by IIF knock-out analysis showed lack of EBMZ reactivity on type VII collagen-negative skin 
compared to normal human skin.7
¶ Patient with accompagnied IgG autoantibodies to laminin-332.35
∑ Patient with accompagnied IgA autoantibodies to plectin.8
¥ accompagnied IgG to resp. plectin meeting two separated diseases: EBA and anti-plectin pemphigoid
Φ had accompagnied IgG to BP230 meeting two separated diseases: EBA and BP.
* Patients also met the criteria of SLE.
In all 20 prospectively identified cases the diagnosis was made by the u-serration pattern, of 
which in 13 cases serum reactivity was absent (Table II). The IIF serum screening on SSS was 
mainly positive in the mechanobullous phenotype in 4 out of 7 (57%) patients compared to 3 
out of 13 (23%) patients with inflammatory EBA/bSLE (Table I, II).
When we add the retrospective serological-positive patients, 38 patients were identified that 
met the criteria of EBA or bSLE (Figure 1). In all skin biopsies the u-serration pattern by DIF was 
positive. Of one patient (#34) no biopsy was available and of one patient (#27) we only had 
a mucous membrane biopsy on which serration pattern analysis can not be performed due 
to lack of overt basal cell rootlets.7 The whole group consisted of 26 females and 12 males. 
Twenty-four (63%) patients had the inflammatory and 14 (37%) the mechanobullous phenotype 
(Table I). Age and gender were equally distributed between the phenotypes (Table III). Mucous 
membrane involvement was present in 22 (58%) patients, and in contrast to what we expected 
more in mechanobullous (9 out of 14, 64%) than in inflammatory (13 out of 24, 54%) EBA/bSLE 
(Table I, III). 



















Age (m ± SD [range]) 50 ± 20 [13-83] 45 ± 16 [19-75] 54 ± 22 [13-83] 56 ± 18 [29-72] 55 ± 16 [29-79] 47 ± 24 [13-83]
Sex: Male N (%) 12 (32%) 5 (36%) 7 (29%) 4 (33%) 2 (18%) 6 (40%)
Mucous membrane 
involvement: N (%)
22 (58%) 9 (64%) 13 (54%) 6 (50%) 6 (54.5%) 10 (67%)
Age presented as mean ± standard deviation (SD) and range. Sex and mucosal involvement presented as 
number (N) and percentage. MB mechanobullous, Inf inflammatory.
88
Chapter 6
A pure IgG isotype response led in 67% of the cases to the mechanobullous phenotype while 
a pure IgA response led in 91% of the cases to the inflammatory phenotype. A mixed response 
led to intermediate percentages, respectively 33% mechanobullous and 67% inflammatory 
(Table IV). Twelve patients had a pure IgG mediated form (Table I, patients 1-12); all had EBA. 
Eleven patients had IgA-EBA (Table I, patients 13-23), and eight of the ten with the inflammatory 
phenotype presented with widespread or localized, linear or circinary small vesicles reminiscent 
of vesicular pemphigoid (VP-like).17 Fifteen cases of EBA/bSLE (Table I, patients 24-38) had a 
mixed IgG/IgA response. One patient #37 had bSLE with an inflammatory, BP-like presentation 
that occurred as an acute inflammatory bullous reaction in systemic lupus erythematosus.  
 table iv. Correlation of clinical phenotype and isotype of in vivo antibody deposition in EBA/bSLE (n=38)







mechanobullous‡ 8 (67%) 1 (9%) 5 (33%) 14
inflammatory‡ 4 (33%) 10 (91%) 10 (67%) 24
mucous membrane involvement 6 (50%) 6 (54%) 10 (67%) 22
‡ Fisher’s exact test p=0.009
DisCUssion
Epidermolysis bullosa acquisita is a rare, heterogeneous autoimmune bullous disease with 
many clinical phenotypes. Immunofluorescence of skin biopsies identifies the disease by the 
characteristic u-serration pattern of immunodeposits along the epidermal BMZ, which was in 
35% of the cases accompanied by serological reactivity to type VII collagen.1,7 Serration pattern 
analysis by DIF disclosed almost three times more EBA patients that most likely remained 
undetected because of negative immunoserology and clinical inflammatory presentation 
indistinguishable from other pemphigoids. Estimated EBA annual incidences in central European 
countries are about 0.25 new cases/million/year.24,25 Zhu and Bystryn found a frequency of 4% 
dermal staining on SSS IF and/or positive immunoblot for type VII collagen among seroreactive 
sAIBD patients.26 In this study we found a frequency of 5.5% EBA/bSLE among patients with 
sAIBD using DIF serration pattern analysis.
EBA may occur at any age, and occurs in both children and adults. The youngest patient (#32) 
is our series was 13 years old. A gender preference is not known, but it is assumed to occur 
slightly more common in females.27-29 In our series there was a predominance (2.2:1) of female 
vs male both in mechanobullous and inflammatory EBA. The ratio of the mechanobullous 
and inflammatory phenotypes of EBA in this study was nearly 1:2, consistent with earlier 
reports that showed a predominance of the inflammatory subtype.26,28 Transition from 
mechanobullous to inflammatory phenotype or vice versa was not found in this study, but has 
been described.30-32 However a temporary flare of widespread inflammatory bullae was noticed 
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in the mechanobullous phenotype during an exacerbartion in a minority of patients. Vice versa, 
development of extensive milia formation and scarring was not seen in any of the inflammatory 
phenotyped patients.
IgA-EBA with exclusively IgA deposits along the epidermal BMZ in a patient with severely 
affected inflammatory skin and mucous membranes was first described by Zambruno.33 In 
our series IgA-EBA patients had widespread or localized vesicles, all but one without larger 
bullae formation. Although mucosal involvement was present in five out of eight patients with 
vesicular pemphigoid-like IgA-EBA, scarring on mucosal surfaces was absent. For four of the 11 
cases a definitive diagnosis of IgA-EBA would not have been reached if serration pattern analysis 
had not been applied, as they had no serum reaction on immunoblot or SSS IIF and a general 
conclusion of LAD would have been made.  
There are two clinical phenotypes of bullous SLE: chronic mechanobullous skin lesions in SLE 
(classic mechanobullous-EBA with SLE), and the acute generalized inflammatory bullae in SLE 
(bSLE in sensu stricto). Our series contained three patients with mechanobullous-EBA and SLE, 
and one patient with bSLE, of which none presented with IgA deposits alone. Although IgA and 
IgG are often present simultaneously along the epidermal BMZ, pure IgA depositions have been 
described in bSLE. 18,34
Intermolecular mechanism of epitope spreading is a known phenomenon also in patients with 
EBA.35,36 Participation of additional autoantigens was present in four patients (10.3%)  (Table 
I, #10, 23, 29 and 33) with reactivity to BP180, BP230, laminin-332 and plectin, suggesting 
intermolecular spreading in the evolution of sAIBD.36,37
Most of our patients had the inflammatory phenotype of EBA/bSLE, that may otherwise have 
been missed and clinically diagnosed as some form of pemphigoid. SSS IIF appeared a less 
sensitive test than serration pattern analysis for identifying EBA. Nevertheless, SSS IIF is far more 
sensitive than conventional IIF on monkey oesophagus.38 One study using recombinant NC1 
ELISA reported extreme high sensitivity (100%) and specificity (100%) for screening EBA.39 Also, 
immunoblot with human placental amnion or cultured A431 cells instead of dermal extract 
might possibly increase the yield in diagnosis.40,41
In conclusion, the clinical phenotype mimics in 63% of the cases other inflammatory types of 
subepidermal autoimmune bullous diseases. Use of DIF serrated pattern analysis triples the 
number of identified EBA/bSLE cases, illustrating the spectrum of clinical variation in patients 
with epidermolysis bullosa acquisita. Without the use of the DIF serration pattern analysis, 
epidermolysis bullosa acquisita stays more often unrecognized when it does not look like the 




Part of this study was presented at the annual meeting of the European Society of Dermatological 
Research in Budapest, Hungary, September 10th, 2009. We are grateful to Janny Zuiderveen, 
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general discussion and future perspectives
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In this thesis we have investigated blistering diseases focusing on the more rare autoantigens. 
Identification of these antigens is not possible with the standard diagnostic test used by most 
laboratories i.e. serum immunofluorescence on monkey esophagus substrate. Therefore we 
used additional techniques as immunoblotting, recombinant antigens, salt-split skin analysis, 
serration pattern examination and knock-out analysis. Especially immunoblotting was useful 
as this enabled us to identify plectin as a minor antigen in pemphigoid (chapter 3) and the 
unexpected finding of low titer anti-BP180 antibodies in the T-cell mediated disease oral lichen 
planus (chapter 4). Also in the ‘white raven’ cases described in chapters 2 and 5 immunoblotting 
was crucial to their discovery. The consequent use of serration pattern analysis of the ‘linear’ 
BMZ immunoglobulin depositions enabled us to identify the EBA patient population that we 
investigated in chapter 6. The availability of the tissue and serum bank of the department that 
contains samples dating back to the mid-seventies of the last century provided us with the 
opportunity to study a large number of sera and biopsies and to calculate the frequencies of 
the more rare diseases.  
In chapter 2 we demonstrated the importance of analysing both patient serum and skin. This 
‘cold case’ patient (she visited our clinic 25 years ago) had a severe blistering disease that remained 
unexplained until 18 years after her death. The final diagnosis was reached trough a combination 
of new techniques not available in those days, and with the standard immunofluorescence 
techniques still in use, most routine laboratories will reach the wrong conclusion even today. 
Serration pattern analysis appeared very crucial here –as also demonstrated in chapter 6 where 
the number of diagnosed cases almost tripled when compared to serum diagnostics - and it 
is clear that skin pathologists should have proper knowledge of the possibilities of serration 
pattern evaluation.    
 In chapter 3 we addressed plectin as a possible antigen in sAIBD. When we started this study 
information on plectin as an autoantigen was limited. One study was known from the literature 
that mentioned plectin as an antigen using a combined immunoprecipitation/immunoblot 
method. Furthermore we ourselves had unexpected found plectin in the ‘white raven’ patient 
described in chapter 2. We found 12 patients (frequency 4%) and using additional techniques 
as knock-out analysis, affinity purification and recombinant constructs we could definitively 
prove that plectin indeed is an antigen of pemphigoid. However from the low frequency and 
the observation that almost always it is present next to the main pemphigoid antigens BP230 
and/or BP80 we conclude it to be a minor antigen. Epitope mapping showed that central coiled-
coil rod domain was most frequently targeted by the autoantibodies, what contrasts with similar 
studies on other plakin family members as periplakin, envoplakin and BP230. Apparently the 
immunodominance of the rod domain as in plectin is not a general feature of the plakin family. 
Plectin is not only present in type I and type II hemidesmosomes, but also in desmosomes.1 As 
such it is also found in skeletal and smooth muscle tissue, and in cardial and nerve tissue.2-4 The 
interesting question is if the antibodies also affect these other tissues. We did find fine dotted 
granular immunoglobulin depositions in arrector pili muscle but do not know if such deposition 
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may lead to pathology. Our study was done retrospectively and no information on this could 
be distilled from the patient files. Future patients however should at least be questioned on 
possible muscle weakness, and measurement of muscle enzymes is an interesting option to 
gain some insight on possible antibody induced muscle pathology.
Immunoblotting also found low titer circulating IgG to a 180 kDa protein in oral lichen planus 
patients. In chapter 4 we showed that this 180 kDa protein is in fact BP180, one of the major 
pemphigoid antigens. Lichen planus is considered a T-cell mediated disease in which cytotoxic 
CD8+ T-cells destroy basal keratinocytes. The antigen to which the T-cells are directed is 
unknown. The circulating BP180 antibodies may be a secondary humoral response resulting 
from exposure of epitopes to the immune system during the primary inflammatory process. 
Such mechanism could be cause of a condition known as lichen planus pemphigoides (LPP). LPP 
is characterized by both lichen planus lesions and subepidermal blisters. Circulating IgG deposits 
linearly along the BMZ and is directed to BP180. The targeted epitope is unique and different 
from the epitopes targeted by pemphigoid patients. Possibly the inflammatory changes in LP 
lesions may lead to some alterations within the BP180 ectodomain creating a novel antigenic 
site in LPP that is different from BP.5 Interestingly, very recent the development of anti-BP180 
MMP was described in two patients with a history of oral lichen planus.6 What we also do not 
exclude is that BP180 is the actual T-cell antigen in the patients described by us. Lichen planus 
in that case could be the T-cell analogue of immunoglobulin mediated blistering disease. In this 
light it is interesting that at the 2010 ESDR meeting it was reported that desmoglein 3-specific 
T-cells induced interface dermatitis in an experimental mouse model.7 
The patient that we describe in chapter 5 had a blistering disease of the skin with widespread 
lesions spreading centrifugally from involved skin to skin that had not blistered before. The 
mucosa were not involved and the diagnosis of anti-laminin 332 pemphigoid was unexpected, 
as classically these patients have blistering of mucous membranes with potential scar formation. 
Immunoblotting on human keratinocyte medium revealed binding of IgG antibodies to proteins 
of 200 and 165 kDa that corresponded with the unprocessed and processed α3 chains of laminin 
332. Immunoprecipitation was negative, thus the epitope is probably cryptic and different 
from the known epitopes on the G domain of the α3 chain of laminin 332.8 Use of this epitope 
therefore might underlie the skin complaints of this particular patient, however such hypothesis 
would need support by further research. 
EBA is considered a relatively rare disease that can have many ‘faces’. The classic form is 
mechanobullous and non-inflammatory but two-third of the EBA patients in chapter 6 
presented with the inflammatory form that can mimic other subepidermal bullous diseases. 
The antibody response can be pure IgG, pure IgA or mixed (IgG/IgA). We sought for a correlation 
between the class of the antibody response and the clinical phenotype. IgA appeared to be 
related with developing the inflammatory form. For the classical mechanobullous type we found 
no association with class response. Possibly the phenotype is also connected with the targeted 
epitope.  In BP180-mediated MMP there is greater use of the carboxy-terminal epitopes than 
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in BP180-mediated bullous pemphigoid.9,10  For mechanobullous EBA the antigenic sites were 
found on the NC1 domain of type VII collagen. For inflammatory EBA the antigenic sites are still 
unknown. We are addressing the possibility of different epitope use in our patients currently in 
a collaborative study with the Universitätsklinikum Schleswig-Holstein in Lübeck. Recombinant 
fusion proteins of the different type VII collagen domains have been produced and the 
reactivity of our sera with these proteins will be tested. Another option to explore is the possible 
contribution of IgE antibodies. Although IgE antibodies are at a 10.000 times lower concentration 
in the human body they can have profound effects on blistering diseases. In bullous pemphigoid 
90% of the patients have anti-BP180 IgE antibodies that are capable of inducing eosinophil 
infiltration and histological blisters in engrafted human skin on SCID mice.11,12 Recently the first 
successful treatment of bullous pemphigoid with omalizumab, a humanized anti-IgE antibody, 
has been reported.13 In our EBA patients 50% had an elevated IgE serum level compared to 
16.6% in the normal population.14 The low overall IgE titer has sofar prevented the analysis of 
floor binding IgE antibodies by salt-split skin immunofluorescence. However seen the sensitivity 
of immunoblotting we hope that such analysis using the recombinant constructs might reveal 
the existence of anti-type VII collagen IgE. Finally the first successful EBA mouse model has just 
been established. Apart from the possibilities to test new therapeutic treatments, such models 
might also be useful to investigate the contribution of epitopes and immunoglobulin class to 
the disease phenotype.
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Subepidermal acquired immunobullous diseases (sAIBD) are characterized by circulating and/
or tissue bound autoantibodies directed to proteins of the epidermal basement membrane 
zone. There are several types of sAIBD, of which some are common and others are more rare. 
Among the common pemphigoids we find bullous pemphigoid, anti-BP180 mucous membrane 
pemphigoid and linear IgA dermatosis, whereas the rare are formed by anti-laminin 332 mucous 
membrane pemphigoid , anti-laminin γ1 pemphigoid, and epidermolysis bullosa acquisita. 
Common or rare are thus in fact defined by the frequency numbers. The calculation of frequency 
numbers however depends on the ability to recognize specific diseases, and thus on the 
discriminating power of the used diagnostic laboratory methods. This thesis is largely dedicated 
to studying rare sAIBD variants.  In chapter 1 we overview the sAIBD, their frequencies, and 
the laboratory techniques used to diagnose them. We furthermore discuss differences in 
immunoglobulin class response and epitope use by the different pathologic antibodies. 
Epidermolysis bullosa acquisita (EBA) is a sAIBD with autoantibodies against type VII collagen. 
Two clinical variants of EBA are recognized: the classic type with trauma-induced blisters with 
milia and dystrophic nails and the inflammatory type with acute blisters on erythematous 
base resembling BP or less commonly MMP. In chapter 2 we studied an exceptional rare case 
of EBA of the inflammatory type, with conflicting diagnostic tests. The diagnosis EBA for this 
patient was originally founded on electron microscopy that revealed the split level to be in the 
sublamina densa zone and later confirmed by the u-serrated pattern of the BMZ immunoglobulin 
deposition. In contrast, salt-split skin analysis revealed the presence of circulating IgA antibodies 
that stained the roof instead of the floor of the blister. By immunoblotting and ‘knock-out’ 
immunofluorescence analysis we could demonstrate these IgA antibodies to be directed to 
plectin. That we did not find circulating antibodies to type VII collagen was not that strange, as 
we will see in chapter 6. This case illustrates that analysis of serum alone might lead to the wrong 
diagnosis and advocates for proper analysis of both skin and serum for sAIBD patients.
Hemidesmosomal proteins are most frequently targeted in sAIBD. Well-characterized 
autoantigens are the intracellular plaque protein BP230, the transmembrane BP180 and its 
shed ectodomain LAD-1. In chapter 3 we describe a fourth hemidesmosomal protein that 
is autoantigen in sAIBD. This protein is plectin that is a member of the plakin protein family, 
similar to BP230, and is found in both hemidesmosomes and desmosomes. In a cohort of two 
hundred and eighty-two sAIBD patients we found 11 patients with anti-plectin antibodies by 
immunoblotting, what gives a relative frequency of 3.9 % among sAIBD. Further proof of the anti-
plectin nature of these antibodies were provided by affinity-purified antibodies that bound back 
to normal human skin in a pattern typical for plectin, i.e. to the epidermal basement membrane 
zone as well as to keratinocytes in the epidermis, and to myocytes, and by the absence of 
binding to plectin-deficient skin of a patient with epidermolysis bullosa simplex with muscular 
dystrophy. The epitopes were mapped by immunoblotting using recombinantly produced 
overlapping plectin domains from the N-terminal actin binding domain to the COOH-end of the 
rod domain. The central coiled-coil rod domain appeared to be the immunodominant hotspot 
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in 10 of 11 sera. Furthermore we found that most patients with anti-plectin antibodies also had 
antibodies to other pemphigoid antigens, and we concluded that plectin is a minor antigen 
in sAIBD. Reviewing the patient files did not reveal a different clinical phenotype compared to 
patients without anti-plectin autoantibodies.
Lichen planus is a chronic inflammatory disease of skin, and oral and genital mucous membranes. 
The histopathology of oral lichen planus (OLP) is quite uniform showing a prominent 
inflammatory band-like lymphocytic infiltrate with liquefactive degeneration of basal epithelial 
cells. In our diagnostic laboratory, sera from patients suffering from inflammatory lesions of the 
oral mucosa are routineously screened for pemphigus and pemphigoid antibodies. We then 
noticed that some patients with proven OLP had weak IgG reactions to a 180-kDa protein by 
immunoblot, which could be BP180. In chapter 4 we further studied this phenomenon in a larger 
series of patients. In sera of forty-seven consecutive patients with defined OLP immunoblotting 
with normal keratinocytes extract showed for eight (17%) sera a reaction with the 180 kDa band. 
To demonstrate that this was BP180 we performed further immunoblot experiments using cell 
extracts of BP180-deficient keratinocytes and of recombinantly produced full-length BP180 and 
overlapping NC16A domain fragments. The reaction to the 180 kDa protein was lost on BP180-
deficient keratinocyte extracts. Five of the eight sera reacted with recombinant full-length-
BP180 and two also reacted with the NC16A domain. The antibody titers were low as all sera 
were negative by indirect immunofluorescence on monkey esophagus substrate, and all but one 
negative on salt-split skin substrate. Direct immunofluorescence of corresponding skin biopsies 
did not show any IgG deposition along the basement zone. Clinically and histologically no 
differences were seen between the eight OLP patients who had anti-BP180 antibodies and OLP 
patients who did not have these antibodies. We suggest that the development of autoantibodies 
might be a secondary, humoral, response to BP180 due to the chronic inflammatory process 
caused by the primary cellular response. Such a process is known as epitope spreading. Whether 
BP180 is also a pathogenic T-cell antigen in OLP needs to be solved.  
Mucous membrane pemphigoid encompasses a group of chronic subepithelial autoimmune 
bullous diseases where predominantly the mucous membranes become affected with the 
potential of scar formation. The autoimmune targets are heterogeneous being BP180 and 
laminin 332 formerly known as epiligrin. When laminin 332 is the antigen the disease is called 
anti-laminin 332 pemphigoid or anti-epiligrin pemphigoid. In chapter 5 we describe a unique 
case of anti-laminin 332 pemphigoid with skin blistering but no involvement of the mucous 
membranes. Immunoblotting on human keratinocyte extracellular matrix using the patient’s 
serum revealed binding of IgG antibodies to bands of 200 and 165 kD corresponding to the 
unprocessed and processed α3 chains of laminin 332. No other antigens were identified by the 
patient’s serum. DIF showed a marked reduction of IgG deposition between the skin in front of 
and behind the wave of blisters, what led us to hypothesize that the direction of blister spread is 
propelled by the difference in IgG load along the epidermal BMZ. 
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The clinical phenotype of EBA can be divided in mechanobullous and inflammatory. In chapter 
6 we investigated if a correlation exists between the isotype of in vivo antibody deposition and 
the clinical phenotype. We performed a prospective cohort study and for the first time included 
patients based on the serration pattern of the immunoglobulin BMZ deposition. Among 364 
sAIBD patients we found 20 (5.5%) cases of EBA/BSLE. When for this same cohort we would 
have included on basis of serological reactivity then only 7 (1.9%) cases would have been 
found. This demonstrates that roughly two in every three EBA patients have no detectable 
serum titre, would have been missed by serum analysis alone and underlines the importance 
of serration pattern analysis of immunodepositions in skin biopsies. Then using serological 
criteria we included an additional 18 retrospective cases of EBA /BSLE using stored samples 
of our tissue/serum bank. Twenty-two (63%) of these 38 cases had the inflammatory subtype 
that mimics other types of subepidermal autoimmune bullous diseases. We sought for possible 
correlation of antibody class and clinical phenotype. In the group with a pure IgG response the 
mechanobullous phenotype dominated (67%), while vice versa in the group with a pure IgA 
response the inflammatory phenotype dominated (91%). No correlation of antibody class or 
phenotype was found with mucous membrane involvement. 
All studies were performed in the Center for Blistering Diseases in Groningen with exception of 
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Subepidermale autoimmuun bulleuze dermatosen (sAIBD) omvatten een groep blaarziekten 
door autoantilichamen die gericht zijn tegen eiwitten in de epitheliale basaalmembraan van 
huid en slijmvliezen. Er zijn verschillende types van sAIBD, waarvan sommige veel voorkomend 
zijn en andere meer zeldzaam. De meest voorkomende vormen van pemfigoïd zijn bulleus 
pemfigoïd, anti-BP180 slijmvliespemfigoïd en lineaire IgA dermatose. De meer zeldzame 
vormen van pemfigoïd zijn anti-laminine-332 slijmvliespemfigoïd, anti-laminine-γ1 pemfigoïd 
en epidermolyse bullosa acquisita. De frequentie van de sAIBD subtypen is afhankelijk van 
het herkennen van bulleuze dermatosen, ook als ze niet met blaren gepaard gaan, en van de 
gebruikte laboratorium technieken en de behaalde detectiedrempels.
Dit proefschrift bevat mijn promotie onderzoek naar ongebruikelijke sAIBD varianten.
In hoofdstuk 1 geven wij een overzicht van de sAIBD, noemen de frequenties en de laboratorium 
technieken om deze te diagnosticeren. Daarna worden de verschillen in immuunglobuline 
klasse bediscussieerd o.a. in het herkennen van epitopen door de verschillende pathogenen 
antilichamen.
Epidermolyse bullosa acquisita (EBA) is een sAIBD met autoantilichamen tegen type VII collageen. 
Twee klinische varianten van EBA worden beschreven: het klassieke mechanobulleuze type met 
trauma-geïnduceerde blaren met milia en dystrofische nagels en het inflammatoire type met 
acute blaren op erythemateuze bodem lijkend op BP of, minder vaak, op slijmvliespemfigoïd. 
In hoofdstuk 2 bestudeerden wij een uitzonderlijke casus met inflammatoire EBA, en 
tegenstrijdige diagnostische testen. De diagnose EBA van deze patient werd bevestigd met 
elektronenmicroscopisch onderzoek wat een splijtingsniveau in de sublamina densa zone 
liet zien. Later onderzoek bevestigde de diagnose op basis van u-serratie patroon van BMZ 
immuundeposities. Zout-gespleten huid toonde juist de aanwezigheid van IgA antilichamen 
in het dak van de blaar aan. Met immunoblot en ‘knock-out’ immunofluorescentie onderzoek 
konden we aantonen dat deze IgA antilichamen gericht zijn tegen plectine. Dat we geen 
circulerende antilichamen tegen type VII collageen vonden was niet zo vreemd, zoals we in 
hoofdstuk 6 zullen zien. Deze casus illustreert dat analyse van alleen serum tot de verkeerde 
diagnose leiden en pleit voor volledige analyse van zowel huid als serum bij sAIBD patiënten.
Hemidesmosomale eiwitten zijn vaak doeleiwit in sAIBD. Goed gekarakteriseerde 
autoantilichamen zijn het intracellulaire plaque eiwit BP230, het transmembrane BP180 of 
het afgesplitste domein LAD-1. In hoofdstuk 3 beschrijven we een vierde hemidesmosomale 
eiwit en autoantigeen in sAIBD. Het eiwit is plectine dat, net als BP230, behoort tot de plakine 
eiwit familie en zowel voorkomt in desmosomen als hemidesmosomen. In een cohort van 
tweehonderd tweeëntachtig sAIBD patiënten vonden wij 11 patiënten met anti-plectine 
antilichamen met immunoblot, wat een relatieve frequentie geeft van 3.9% onder sAIBD. 
Verder bewijs voor de anti-plectine aard van deze antilichamen werd gevonden door affiniteits-
gezuiverde antilichamen terug te binden aan normale huid in een patroon typisch voor plectine: 
langs de epidermale basale membraan zone (BMZ), rond keratinocyten in de epidermis, en aan 
myocyten. Dit bindingspatroon trad niet op in een huid biopt van een patiënt met plectine-
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deficiënte epidermolysis bullosa simplex met spierdystrofie. De epitopen werden gemapt 
door immunoblot met recombinant  geproduceerde overlappende plectine domeinen van 
het N-terminale actine bindingsdomeiin van het COOH-eind van het rod domein. Het centrale 
coiled-coil rod domein bleek de immuno-dominante hotspot in 10 van 11 sera. Verder vonden 
we dat de meeste patiënten met anti-plectine antilichamen ook antilichamen voor andere 
pemfigoïd antigenen hebben, en we concludeerden dat plectine zeldzaam auto-antigeen is in 
sAIBD. 
Lichen planus is een chronische inflammatoire ziekte van de huid en slijmvliezen. De 
histopathologie van orale lichen planus (OLP) is vrij uniform: een prominent inflammatoir 
bandvormig ontstekingsinfiltraat met liquefactie van basale epitheliale cellen. In ons 
diagnostisch laboratorium worden sera van patiënten met afwijkingen in de mondholte 
gescreend voor pemphigus en pemfigoïd. Het viel ons toen op dat sommige patiënten met 
bewezen OLP zwakke IgG reacties tegen een 180-kDa eiwit hadden bij immunoblot, dat BP180 
kan zijn. In hoofdstuk 4 bestudeerden wij dit fenomeen in een grotere groep patiënten. In 
sera van zevenenveertig opeenvolgende patiënten met bewezen OLP vonden wij acht (17%) 
sera die reageerden met het 180-kDa eiwit. Om aan te tonen dat dit om BP180 ging voerden 
wij verder immunoblot experimenten uit met celextract van BP180-deficiënte keratinocyten 
en met recombinant full-length BP180 en overlappende NC16A domein fragmenten. De 
serum reactiviteit met het 180 kDa eiwit ging verloren bij immunoblot op BP180-deficiënte 
keratinocyten extract. Vijf van de acht sera reageerden met recombinant full-lenght-BP180 
en twee reageerden ook met het NC16A domein oligopeptide. De antilichaam titers waren 
laag, zodat er met indirecte immuunfluorescentie op apenoesophagus geen reactie was, en 
behalve één serum was alles negatief op zout-gespleten huid. Directe immunofluorescentie 
op de corresponderende huid biopten liet géén IgG deposities zien langs de BMZ. Klinisch en 
histologisch was er geen verschil tussen de acht OLP patienten die circulerende anti-BP180 
antilichamen hadden en OLP patiënten die deze autoantilichamen niet hadden. Wij denken 
dat de ontwikkelling van autoantilichamen mogelijk een secundaire, humorale, respons is van 
BP180 door het chronisch ontstekingsproces veroorzaakt door de primaire cellulaire respons. 
Zo’n proces is bekend als het ‘epitoop spreading’ fenomeen. Of BP180 ook een pathogeen 
antigeen is voor T-cellen in OLP moet nog verder onderzocht worden.
Slijmvliespemfigoïd omvat een groep chronische subepitheliale autoimmuun bulleuze 
dermatosen waarbij er slijmvliesafwijkingen zijn, met risico op littekenvorming. De autoimmuun 
doeleiwitten zijn heterogeen, waaronder BP180 en laminin-332, de laatste eerder bekend als 
epiligrin. Als laminin-332 het antigeen is, wordt de ziekte anti-laminin-332 pemfigoïd genoemd 
of anti-epiligrine pemfigoïd. In hoofdstuk 5 beschrijven wij een bijzondere casus van anti-
laminine-332 pemfigoïd met blaarvorming van de huid, maar zonder slijmvliesdeelname. 
Immunoblot op humaan keratinocyten medium extract toonde bandjes van IgG antilichamen bij 
200 en 165 kD, corresponderend met het propeptide en de verwerkte α3 keten van laminine-332. 
Er werden geen andere antigenen gevonden in het serum van de patiënt. De huidaandoening 
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verliep met een centrifugale golven van blaarvorming. Directe immunofluorescentie toonde 
een opvallende reductie van IgG deposities in de huid als de blaargolf gepasseerd was. Het 
verschil in IgG oplading langs de epidermale BMZ verklaart de centrifugale spreiding van de 
blaarvorming.
Het klinisch fenotype van EBA kan worden verdeeld in mechanobulleus en inflammatoir. 
In hoofdstuk 6 onderzoeken we of er een relatie bestaat tussen het klinische fenotype en 
de klasse van in vivo gedeponeerde antilichamen. We voerden een prospectieven studie uit 
van patiënten, geselecteerd op het serratiepatroon van immuunglobuline BMZ deposities. 
In een cohort van 364 sAIBD patiënten vonden wij 20 (5.5%) patiënten met de diagnose EBA 
of bulleuze SLE(BSLE). Als we alleen patiënten op basis van serologische reactiviteit hadden 
geïncludeerd zouden er slechts 7 (1.9%) casus gevonden worden. Dit betekent dat, twee van 
de drie patiënten gemist zouden worden als er geen serratiepatroon analyse wordt toegepast 
op het IF biopt, omdat het serum geen detecteerbare autoantilichamen toont die passen bij 
EBA. Met behulp van serologische criteria konden we aanvullend 18 retrospectieve EBA/BSLE 
patiënten includeren uit de weefsel/serum opslag. Tweeëntwintig (63%) van deze 38 casus 
hadden het inflammatoire type dat lijkt op andere typen van sAIBD’s. Wij zochten naar een 
mogelijke relatie van antilichaam klasse en klinische fenotype. In de groep van puur IgG respons 
was het mechanobulleuze fenotype overheersend (67%), terwijl vice versa in de groep van pure 
IgA respons het inflammatoire fenotype dominant was (91%). Er was geen correlatie tussen de 
antilichaam klasse of het fenotype met de aanwezigheid van slijmvliesdeelname. 
Alle studies werden uitgevoerd in het Centrum voor Blaarziekten in Groningen met uitzondering 
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